Drug, bio-affecting and body treating compositions inventions 09/07

20070225246 - O-acetyl-adp-ribose non-hydrolyzable analogs: Compounds, compositions and methods for modulating cell death in target cells, particularly cancer cells are provided. The compounds are analogs of O-acetyl-ADP-ribose (OAADPr).... Agent: Brinks Hofer Gilson & Lione

20070225202 - Methods for identifying modulators of active kit tyrosine kinase receptor: The present invention relates to cell-based assays useful for screening for modulators, such as inhibitors, of activated mutant KIT tyrosine kinase receptors, which are associated with mast cell-related disorders, such as mastocytosis and various types of cancer. The invention further provides for the treatment of mast cell-related disorders with an... Agent: Marshall, Gerstein & Borun LLP

20070225206 - Biomarkers for osteoarthritis: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits... Agent: Klarquist Sparkman, LLP

20070225209 - Compositions and methods for treating neurological disorders and diseases: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070225207 - Group 1 mite polypeptide variants: This invention concerns variants of a group 1 mite polypeptide, wherein the mature polypeptide of the variants comprise one or more mutations in the positions or corresponding to positions consisting of P11, I14, D15, L16, M19-P24, Q28, F37, S38, T43, A46-A49, Q53-L57, V63, A66-H69, H72, D74-R77, I80, Y82, Q84, H85,... Agent: Novozymes North America, Inc.

20070225204 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070225205 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070225203 - Method and composition for preventing multiple organ dysfunction syndrome: One aspect of the present invention relates to a method of preventing multiple organ dysfunction syndrome in a mammal suffering from trauma, said method comprising enterally administering to said mammal, within 24 hours of the occurrence of the trauma, (i) digestible water soluble carbohydrates and (ii) a liver guanosine-5′-triphosphate (GTP)... Agent: The Webb Law Firm, P.C.

20070225208 - Use of fibrin for separating body organs: The present invention relates to the use of coagulant or gellifying substances for administration into body sites with the aim of obtaining the temporary separation of said organs. The invention also relates to a method for the separation of body sites and a related administration kit using said substances.... Agent: Dickstein Shapiro LLP

20070225211 - Methods and formulations for increasing intestinal function: A method for increasing intestinal function is provided. The method comprising orally and/or enterally administering to a subject in need thereof a therapeutically effective amount of insulin, thereby increasing intestinal function.... Agent: Martin D. Moynihan Prtsi, Inc.

20070225210 - Therapeutic vaccine compositions for the treatment of type 1 diabetes: The invention concerns therapeutic vaccine compositions that comprise modified Insulin B chain components suitable for use as immunogenic agents for treatment and prevention of Type 1 Diabetes.... Agent: Thomas Hoxie, Esq. Hoxie & Tso LLP

20070225212 - Use of a peptide: The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.... Agent: Novo Nordisk, Inc. Patent Department

20070225213 - Nucleic acid carriers for delivery of therapeutic agents: Nucleic acid drug carriers comprise a nucleic acid carrier complexed with a drug, wherein the nucleic acid carrier and the drug are associated non-covalently, and optionally other agents such as spacer, transfection agents, and targeting agents. The nucleic acid drug complex are discovered to have permissive or refractory uptake depending... Agent: Matthew K. Kosak

20070225214 - Use of osteopontin for the treatment and/or prevention of neurologic diseases: The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070225215 - Modulation of cartilage homeostasis by active domains of cell binding extracellular matrix molecules: A linear or cyclic peptide and the use of said peptide in medicine and especially in the manufacture of a medicament for the treatment and/or prophylaxis of a disease associated with inflammatory mediated cartilage destruction. The minimal core sequence of the linear or cyclic peptide is WLEAK. Alternatives are WLEAR... Agent: Lynn E Barber

20070225216 - Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis: The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce... Agent: Perkins Coie LLP

20070225217 - Methods, compositions, and kits for the treatment of medical conditions: The invention features methods, compositions, and kits for treating an immunoinflammatory disorder, an ophthalmic disorder, a musculoskeletal disorder or pain associated therewith, a periodontal disease, or a disease or condition associated with an increased serum CRP level.... Agent: Clark & Elbing LLP

20070225220 - Antimicrobial composition: An antimicrobial composition comprising (a) a cationic surfactant derived from the condensation of fatty acids and esterified dibasic amino acids, such as lauric arginate and (b) an antibiotic, such as of β-lactam antibiotics, polypeptides, quinolones. The composition may be used as a stand alone antimicrobial formulation, or in combination with... Agent: Philip S. Johnson Johnson & Johnson

20070225228 - Blockade of gamma-secretase activity to promote myelination by oligodendrocytes: Methods are provided for enhancing myelination. Myelination is enhanced by administration of agents that are inhibitors of γ-secretase. Methods of screening for pharmaceutically active compounds that enhance myelination, and for genes involved in myelination are also provided.... Agent: Bozicevic, Field & Francis LLP

20070225226 - C-reactive protein apheresis: The present invention provides ligands that can bind CRP with high affinity and high specificity. The present invention also provides a method of treating a condition of elevated CRP through apheresis, by reducing CRP level via its binding to a CRP-specific ligand ex vivo. Systems of performing apheresis to reduce... Agent: Foley And Lardner LLP Suite 500

20070225218 - Extracellular messengers: Various embodiments of the invention provide human extracellular messengers (EXMES) and polynucleotides which identify and encode EXMES. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of EXMES.... Agent: Foley And Lardner LLP Suite 500

20070225219 - Intramedullary drug delivery device and method of treating bone fractures: An intramedullary drug delivery device is disclosed and can be inserted within a bone canal of a bone. The intramedullary drug delivery device can include a housing. A drug delivery region can be established along the housing. Also, the drug delivery region can be configured to substantially span a fracture... Agent: Larson Newman Abel Polansky & White, LLP

20070225227 - Lipoparticles comprising ion channels, methods of making and using the same: The present invention relates to the use of lipoparticles, virus-like particles, and viruses. The present invention also relates to testing ion channel function and modulators of ion channels.... Agent: Morgan, Lewis & Bockius LLP

20070225221 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070225223 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20070225224 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20070225229 - N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20070225222 - Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer: The FNIII13 domain of fibronectin and smaller fragments thereof have a tumour cell proliferation inhibitory effect. Compositions are provided comprising fragments of fibronectin having the FNIII 13 domain and fragments thereof. A system comprising cells exposed to fibronectin and caused to proliferate by the presence of tenascin are used as... Agent: Novartis Corporate Intellectual Property

20070225225 - Use of natriuretic peptide receptor antagonists to treat ocular, otic and nasal edemetous conditions: Methods and compositions to treat edematous ocular, otic and nasal conditions are described.... Agent: Alcon

20070225230 - Vehicle for the transport of a chosen molecule to a cell: Vehicle for the transport of a chosen molecule to a cell, comprising a SAINT-molecule which is bound to the chosen molecule by means of an electrostatic interaction, in which the SAINT-molecule is coupled to the linker molecule and the linker molecule is coupled to the cell specific ligand and in... Agent: Peacock Myers, P.C.

20070225231 - Methods for inhibiting immune complex formation in a subject: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation, are described.... Agent: Fish & Richardson P.C.

20070225232 - Tetrahydro-imidazo [1,5-a] pyridyin derivatives as aldosterone synthase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070225233 - Reducing the risk of chronic lung disease in infants: Described herein is a method for reducing the risk of chronic lung disease in an infant suffering from respiratory distress syndrome by administering to the infant a combination of a corticosteroid having a high local to systemic anti-inflammatory activity (e.g., budesonide) and a lung surfactant.... Agent: Fish & Richardson PC

20070225235 - Methods for the prevention and/or the treatment of glutamate cytotoxicity: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives,... Agent: Buchanan, Ingersoll & Rooney PC

20070225234 - Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect: A topical formulation of the oil-in-water type comprising an oily material, an aqueous phase and an emulsifier, wherein the emulsifier is a galactolipid material, as a carrier for providing a reduced irritant effect of an incorporated active substance on the skin. New topical formulations are also described.... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20070225236 - Methods for the prevention and/or the treatment of glutamate cytotoxicity: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives,... Agent: Buchanan, Ingersoll & Rooney PC

20070225237 - Methods for the prevention and/or the treatment of glutamate cytotoxicity: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and /or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone... Agent: Buchanan, Ingersoll & Rooney PC

20070225238 - Inhibitors of carbonyl reductase for treatment using anthracyclines: Compositions of matter and methods of using the compositions of matter are disclosed for preventing or reducing cardiotoxicity during or after cancer treatment with anthracycline drugs, and preventing or reducing resistance to anthracycline drugs, both of which are believed to be caused by human enzyme carbonyl reductase. Thus, the compositions... Agent: Pedersen & Company, PLLC

20070225239 - Pna-neamine conjugates and methods for producing and using the same: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant... Agent: Licatas & Tyrrell

20070225244 - Compositions comprising genome segments and methods of using the same: Methods of treating an individual who has a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA of the individual, or preventing an individual from developing a disease or disorder associated with one or more genetic mutations or undesirable alleles in genomic DNA... Agent: Pepper Hamilton LLP

20070225242 - Method and composition for treating and preventing tumor metastasis in vivo: Methods, compositions and kits are provided for effectively treating and preventing cancer metastasis in vivo and for increasing survival of subjects burdened with metastatic tumors by targeting a lysyl oxidase or its modulator, especially human lysyl oxidase. Also provided are methods for identifying lysyl oxidase inhibitors and the use of... Agent: Peters Verny , L.L.P.

20070225240 - Screening assay and treatment: The invention relates to screening assays for the identification of agents which modulate the activity of polypeptides which affect the apoptotic activity of the tumour suppressor protein p53 and including gene therapy vectors comprising p53 and antibodies that bind phosphorylated epitopes.... Agent: Klarquist Sparkman, LLP

20070225241 - Tfiis and gdown1 as targets for cancer therapy: The present invention concerns cancer therapy related to the targeting of at least one core transcription factor. In particular, the compositions and methods of the invention concern targeting TFIIS, GDOWN1, or both for cancer therapy. In specific aspects, TFIIS and/or GDOWN1 inhibitors are employed for breast, prostate, pancreatic, and/or lung... Agent: Fulbright & Jaworski, LLP

20070225243 - Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor: The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ω and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070225245 - Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof: The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with... Agent: Benjamin Aaron Adler Adler & Associates

20070225247 - Process for preparing an a2a-adenosine receptor agonist and its polymorphs: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.... Agent: Cv Therapeutics, Inc.

20070225249 - 2'-fluoronucleoside phosphonates as antiviral agents: The present invention includes compounds and compositions of R-2′-fluoronucleoside phosphonates, as well as methods to treat HIV, HBV, HCV or abnormal cellular proliferation comprising administering said compounds or compositions.... Agent: Nutter Mcclennen & Fish LLP

20070225248 - Oral dosage forms of gemcitabine derivatives: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in... Agent: Fitzpatrick Cella Harper & Scinto

20070225250 - Cobalamin compositions for the treatment of cancer: Compositions are provided that contain a combination of a nitric oxide-cobalamin complex along with at least one cobalamin drug conjugate, together with methods for their use in the treatment of neoplastic disease.... Agent: Proskauer Rose LLP

20070225252 - Ketogenic saccharides: A novel ketogenic compound is provided having general formula (R(OCH(CH3)CH2C(O))nO)m-A wherein n is a integer between 1 and 10, m is an integer of 1 to 200,000, A is a monsaccharide, polysaccharide or oligosaccharide residue and R is selected from the group consisting of H, C1-C6 alkyl and acetoacetyl-.... Agent: Nixon & Vanderhye, PC

20070225251 - Method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration: Oligosaccharides, and in particular disaccharides, which are degradation products of chondroitin sulfate proteoglycan are effective for use in treating, inhibiting, or ameliorating the effects of injuries or diseases or disorders that result in or are caused by neuronal degeneration or of disorders resulting in mental and cognitive dysfunction.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070225253 - Use of a trioxopyrimidine for the treatment and prevention of bronchial inflammatory diseases: The invention provides the use of a trioxopyrimidine compound having an inhibitory activity against MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 defined as a) an IC50 value of less than 5 μM for MMP-2, MMP-9 and MMP-14 each; b) a ratio of more than 100 for the IC50 values of MMP-1:MMP-2,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070225254 - Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide- based compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.... Agent: Townsend And Townsend And Crew, LLP

20070225255 - Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers: The present invention relates to the use of a mitochondrially targeted antioxidant, e.g. derivatives of vitamin E, coenzyme Q10 or a glutathione peroxidase mimetic, in the treatment and prevention of liver diseases and/or epithelial cancers. The present invention also relates to pharmaceutical compositions containing the antioxidant(s) intended for such use.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070225256 - Compound: The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of —OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the A ring of the steroidal ring system is optionally substituted... Agent: Frommer Lawrence & Haug

20070225257 - Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof: e

20070225258 - Compositions comprising bisphosphonate and an antifolate: Compositions and methods for the treatment of arthritis, particularly rheumatoid arthritis and osteoarthritis. These compositions include at least one antifolate and at least one bisphosphonate, or pharmaceutically acceptable salts thereof... Agent: Knobbe Martens Olson & Bear LLP

20070225259 - Novel thiazole inhibitors of fructose 1,6-bishosphatase: Compounds of Formula I, their prodrugs and salts, their preparation and their uses are described.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070225260 - Amino-propanol derivatives: A compound of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.... Agent: Novartis Corporate Intellectual Property

20070225261 - Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also... Agent: Morrison & Foerster LLP

20070225262 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20070225263 - Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma: The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal and optic nerve damage associated with glaucoma.... Agent: Alcon

20070225264 - Drug delivery means: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments,... Agent: Robert C. Atkinson Simpson & Simpson, PLLC

20070225267 - 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.... Agent: Eli Lilly & Company

20070225265 - Novel macrocycles for the treatment of cancer: The present invention relates to new macrocycles of the general formula (I) as their use for the treatment of cancer diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20070225266 - Spiropiperidylrifamycins for the treatment of mycobacterial infections: The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R3 is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions... Agent: Berenbaum, Weinshienk & Eason, P.c

20070225268 - Method to treat neoplasms via gadolinium stereotactic synchrotron radiation: Described is a method of inhibiting the growth of neoplastic cells. The method includes the steps of contacting neoplastic cells with a gadolinium-containing compound for a time sufficient to allow the gadolinium-containing compound to be internalized within the neoplastic cells. The neoplastic cells are then exposed to a photon flux... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20070225271 - Pyrimidine, quinazoline, pteridine and triazine derivatives: wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070225270 - Pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070225269 - Use of (3-(1-(3-phenyl-propenyl)-piperidin-4-yl)-2,3-dihydro-indol-1-yl)-(pyridin-4-yl)-methanonone derivatives and related compounds as insecticides: The use of a compound of formula (I): R3 N YR1(I) wherein Y is a single bond, C═O, C═S or S(O)71 where m is 0, 1 or 2; R1, R2, R3, R4, R8 and Ra are specified organic groups and p is 0, 1, 2, 3, 4, 5 or 6;... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070225272 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.... Agent: Merck And Co., Inc

20070225273 - Malonamide derivatives: h

20070225274 - Methods for modulating bladder function: This invention provides methods and pharmaceutical compositions for modulating bladder function, and in particular for maintaining bladder control or treating urinary incontinence.... Agent: Choate, Hall & Stewart LLP/wyeth

20070225275 - Tetrahydro-pyrimidoazepines as modulators of trpv1: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be-administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.... Agent: Philip S. Johnson Johnson & Johnson

20070225276 - 7-phenylsulfonyl-tetrahydro-3-benzazepine dervatives as antipsychotic agents: R3 and R4 independently represent hydrogen or C1-6alkyl; and a pharmaceutically acceptable salt and solvate thereof; with the proviso that the compound {8-[4-(4-fluoro-benzyl)-benzenesulfonyl]-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-dimethyl-amine is excluded. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are useful in therapy, in particular as antipsychotic agents.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070225278 - Methods for treating cognitive and other disorders: This invention provides methods and pharmaceutical compositions for treating cognitive disorders such as learning disorders and ADD/ADHD, and other disorders.... Agent: Choate, Hall & Stewart LLP/wyeth

20070225279 - Therapeutic combinations for the treatment of depression: i

20070225277 - Treatment of pain:

20070225280 - Adamantyl-pyrazole carboxamides as inhibitors of 11b-hydroxysteroid dehydrogenase:

20070225281 - 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators: Compounds having the structure of formula I are provided. In formula I, R1 is H, OH, substituted or unsubstituted C1 to C3 alkyl, C1 to C3 perfluoroalkyl, or COR6; R6 is H, substituted or unsubstituted C1 to C4 alkyl, aryl, substituted or unsubstituted C1 to C4 alkoxy, substituted or unsubstituted... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20070225282 - Pyridines and pyridine n-oxides as modulators of thrombin: m

20070225285 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070225283 - Conformationally restricted urea inhibitors of soluble epoxide hydrolase: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.... Agent: Townsend And Townsend And Crew, LLP

20070225284 - Inhibitors of soluble adenylate cyclase: The invention relates to compounds of general formula I as well as the production and use thereof as a medication.... Agent: Millen, White, Zelano & Branigan, P.C.

20070225286 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3,... Agent: Novartis Corporate Intellectual Property

20070225287 - Substituted arylpyrazines: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and... Agent: Neurogen Corporation

20070225288 - Indene derivatives and process for the preparation thereof: The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism... Agent: Anderson, Kill & Olick, P.C.

20070225290 - Tetrahydronaphthalene derivates, processes for preparing them and their use as antiinflammatory agents: e

20070225289 - Topoisomerase-targeting agents: the bond represented by — is a single bond or a double bond, and R1-R5, X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds... Agent: Viksnins Harris & Padys Pllp

20070225291 - Substituted pyrazinone compounds for the treatment of inflammation: Kinase inhibitors of Formula (I): wherein X, Ra, Rb, Rc, and Rd are as defined herein, are disclosed.... Agent: Pfizer Inc.

20070225292 - Therapeutic compounds: pyridine as scaffold: n

20070225293 - Use of c-kit inhibitors for treating fibrosis: The present invention relates to a method for treating fibrosis and related disorders comprising administering a compound capable of depleting mast cell or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective... Agent: Foley And Lardner LLP Suite 500

20070225294 - Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors: wherein R1-R5, R25, R26, Y, y, and X2 are as defined herein. The compounds activate human peroxisome proliferater activated receptors (hPPARs) and are useful for the treatment of associated disorders such as dyslipidemia, syndrome X, hypercholesteremia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, and obesity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070225295 - Ziprasidone hydrochloride polymorph and process for its preparation: New crystalline form of ziprasidone hydrochloride hemihydrate, process for its preparation, its use for the purification of ziprasidone, its pharmaceutical compositions and their use in therapy.... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20070225296 - Arylalkylamine compound and process for preparing the same: w

20070225297 - Deuterated hepatitis c protease inhibitors:

20070225298 - Method for controlling fungi and mites in textile substrates: The present invention, therefore, relates to a method for prophylaxis, control or reduction of fungi in a textile substrate, which comprises applying to a textile substrate that is susceptible to fungal infestation an amount effective for the prophylaxis, control or reduction of fungi of at least one fungicidal compound. The... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070225299 - Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance: A combination product which comprises as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, where active ingredient component A is a direct soluble guanylate cyclase stimulator of the formula (I) and active ingredient component B is a lipid-lowering agent, is... Agent: Jeffrey M. Greenman

20070225301 - Treatment of acne and other diseases: The invention relates to compounds for the treatment of dermatological diseases where inflammation, matrix metalloproteinases (MMPs) and peroxisome proliferator-activated receptors (PPARs) play a role in mediating the disease, such as the treatment of acne with Pemirolast or a closely related compound thereof.... Agent: Foley And Lardner LLP Suite 500

20070225300 - Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives: X, Y, R1, R2, R3, R4, R5, m, n and p are as defined herein. In particular, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070225302 - 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents:

20070225303 - 8-oxoadenine compound: X1 is oxygen atom, Z is straight or branched chain alkylene, and R1 is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.... Agent: Birch Stewart Kolasch & Birch

20070225304 - Aminopurine derivatives for treating neurodegenerative diseases: The invention relates to aminopurine derivatives useful in treating disorders that are mediated by adenosine receptor function, including neurodegenerative diseases and inflammation. The compounds are of the general formula:... Agent: Heslin Rothenberg Farley & Mesiti PC

20070225305 - Preparation of ester of purine derivatives: A process for the preparation of valganciclovir with triacetyl ganciclovir (V) as a starting material, comprising the following steps: selective hydrolysis, reacting with a coupling agent and a solvent, followed by hydrolysis under basic conditions and hydrogenolysis in the presence of a catalyst.... Agent: Hedman & Costigan P.C.

20070225306 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3,... Agent: Genomics Institute Of The Novartis Research Foundation

20070225307 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Leydig Voit & Mayer, Ltd

20070225308 - 2-amino quinazoline derivative: e

20070225309 - Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors:

20070225310 - Antiviral methods and compositions: Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20070225311 - 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists: in which the R1 group is as defined in the specification and includes the condensation of 7-t-butoxyiminomethylcamptothecin in position 20 with a cyclopeptide containing the RGD sequence. Said compounds are endowed both with high affinity for integrin receptors αvβ3 and αvβ5 and with selective cytotoxic activity on human tumour cell... Agent: Nixon & Vanderhye, PC

20070225312 - Terguride / proterguride for the treatment of chronic pain: The present invention relates to the use of terguride and proterguride for the prophylaxis and/or the treatment of chronic pain conditions as well as to pharmaceutical compositions comprising terguride and/or proterguride optionally together with an opiate analgesic.... Agent: J C Patents, Inc.

20070225313 - Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same: Epimers and isomers of tetrazole-containing rapamycin analogs and a pharmaceutically acceptable salt or prodrug thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method... Agent: Philip S. Johnson Johnson & Johnson

20070225316 - Methods and compositions for treating schizophrenia: The present invention relates to methods and compositions useful for treating, preventing and/or delaying the onset and/or development of schizophrenia by administering a hydrogenated pyrido[4,3-b]indole, such as dimebon, or a pharmaceutically acceptable salt thereof, to an individual.... Agent: Morrison & Foerster LLP

20070225315 - Methods of treating muscular wasting diseases using nf-kb activation inhibitors: Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment for a muscular wasting disease, an NF-κB activation inhibitor capable of blocking the activation of NF-κB.... Agent: Senniger Powers

20070225314 - Novel forms of tiotropium bromide and processes for preparation thereof: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070225317 - Rsv polymerase inhibitors: i

20070225319 - Piperidinyl indole and tetrohydropyridinyl indole derivatives and methods of their use: 3-Piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed. Methods of using the derivatives and compositions containing the derivatives in the prevention and/or treatment of serotonin disorders, such as depression and anxiety, are also disclosed. Additionally, processes for the preparation of 3-piperidin-4-yl-1H-indole and 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole derivatives are disclosed.... Agent: Woodcock Washburn LLP/wyeth

20070225318 - Pyrazole compounds useful in the treatment of inflammation: There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in... Agent: Morgan Lewis & Bockius LLP

20070225320 - Process for preparing clopidogrel: A process for preparing clopidogrel or a salt thereof.... Agent: Dr. Reddy's Laboratories, Inc.

20070225321 - 2,4-pyrimidinediamine compounds and their uses: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized... Agent: Rigel Pharmaceuticals Inc.

20070225322 - Compositions and methods for treating middle-of-the night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: O'melveny & Myers LLP

20070225323 - Substituted 4-phenyltetrahyrdoisoquinolines, pharmaceutical compositions thereof, methods for their preparation and therapeutic use: and pharmaceutical compositions comprising them wherein the R groups are herein defined. These are excellent inhibitors of the sodium-hydrogen exchanger (NHE), in particular of the sodium-hydrogen exchanger of subtype 3 (NHE3). As such these compounds are useful in the treatment of various disorders of the renal and respiratory systems such... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070225324 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: d

20070225327 - Biaryl sulfonamides and methods for using same: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.... Agent: Woodcock Washburn LLP/wyeth

20070225326 - Montelukast amantadine salt: An amantadine salt of montelukast is useful in purification of montelukast or its salts and as a pharmaceutical active ingredient.... Agent: SynthonIPInc

20070225325 - Solid forms of montelukast acid: Differing forms of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid and methods for synthesizing same.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20070225329 - Aryl aniline beta2 adrenergic receptor agonists: wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates... Agent: Theravance, Inc.

20070225328 - Synthetic nacre: A method of manufacturing sustainable biominerals such as nacre is described. Furthermore, synthetic self-organizing biominerals, in particular synthetic nacre is provided.... Agent: Cooper & Dunham, LLP

20070225330 - Use of certain phenyl-naphthyl compounds that do not have significant affinity to er alpha or er beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis: The invention provides a new use for certain SERM-like phenylnaphthyl compounds that do not exhibit affinity for alpha or beta type estrogen receptors (ER) in the treatment of multiple sclerosis.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070225331 - 4,4-disubstituted piperidines, and methods of use thereof: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments,... Agent: Edwards Angell Palmer & Dodge, LLP

20070225332 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: e

20070225333 - 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin via receptor: Compounds of formula (I): or a pharmaceutically acceptable derivative thereof, wherein R represents C1-6alkyl (optionally substituted by C1-6alkyloxy or Het) or C1-6alkyloxy; R1 and R2 independently represent hydrogen, halo or C1-6alkyl, ring A represents Het1; X represents O or NR3; R3 represents hydrogen or C1-6alkyl; ring B represents a phenyl... Agent: Pfizer Inc.

20070225334 - Methods for treating cognitive and other disorders: This invention provides methods and pharmaceutical compositions for treating cognitive disorders such as learning disorders, ADD/ADHD, and other disorders.... Agent: Choate, Hall & Stewart LLP/wyeth

20070225336 - Anthropodicidal anthranilamides: R1, R2, R3, R4a, R4b and R5 are as defined in the disclosure. Also disclosed are methods for controlling invertebrate pests comprising contacting the invertebrate pests or their environment with a biologically effective amount of a compound of Formula 1 or a composition comprising a compound of Formula 1.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20070225335 - Pyrazole derivatives for treating condit ions mediated by activation of the adeno sine a2b or a3 receptor: in free or salt form, wherein R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating a condition mediated by activation of the adenosine A2b receptor or the adenosine A3 receptor, particularly an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the... Agent: Novartis Corporate Intellectual Property

20070225337 - Novel co-precipitate of amorphous rosiglitazone: A novel coprecipitate of amorphous rosiglitazone maleate with a pharmaceutically acceptable carrier, e.g. polyvinylpyrolidone, mannitol, lactose, methylcellulose, cyclodextrin or silicon dioxide, a process for the preparation of said novel co-precipitate and the use of said novel coprecipitate of amorphous rosiglitazone with a pharmaceutically acceptable carrier in the treatment and/or prophylaxis... Agent: Novartis Corporate Intellectual Property

20070225338 - Juvenile hormone analogs for control of leafhopper and treehopper pests: The present invention pertains to compounds and methods for controlling treehopper and leafhopper pests, such as the glassy-winged sharpshooter (GWSS), while conserving their parasites (such as parasitoid wasps). In one embodiment, the compound is a juvenile hormone analog such as methoprene, kinoprene, and hydropene. The invention also concerns pesticidal compositions... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070225339 - Compositions and methods for treating rheumatoid arthritis: The present invention relates to methods and compositions for treating RA in subjects in need thereof. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.... Agent: Vertex Pharmaceuticals Inc.

20070225340 - Phenyl compounds and their use in the treatment of conditions mediated by the action of pge2 at the ep1 receptor: e

20070225341 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20070225342 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20070225343 - Pharmaceutical latrunculin formulations: The present invention relates to an aqueous pharmaceutical formulation comprising at least one latrunculin and the formulation does not contain a substantial amount of dimethyl sulfoxide. In one embodiment, the present invention is directed to an aqueous pharmaceutical formulation comprising at least one latrunculin in an amount of 0.001-2% w/v,... Agent: Howery LLP

20070225344 - Sulfonamide derivatives to treat infection with hepatitis c virus: e

20070225345 - Therapeutic substituted cyclopentanones:

20070225346 - Crystalline forms: A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070225347 - Imidazole derivatives: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and X′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20070225348 - Amino acid composition for improving glucose tolerance: Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070225349 - Substituted 4-(indazol-3-yl)phenols: R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease,... Agent: Woodcock Washburn LLP/wyeth

20070225350 - Compositions and methods for treating neoplastic diseases: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.... Agent: Knobbe Martens Olson & Bear LLP

20070225351 - Methods and compositions for controlling body weight and appetite: The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease,... Agent: Black Lowe & Graham PLLC Jeffrey J. King, Esq.

20070225352 - Novel androgens: e

20070225353 - Process for forming amorphous atorvastatin: Forming amorphous atorvastatin comprises the steps of dissolving atorvastatin in a solvent to form a solution, followed by adding the solution to a mixture comprising a non-solvent and a hydroxylic solvent to afford amorphous atorvastatin.... Agent: Warner-lambert Company

20070225355 - Dietary compositions for enhancing metabolism and reducing reactive oxygen species: This invention relates to dietary compositions and to methods for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a composition comprising a combination of carnitine, lipoic acid and polyphenol, which has the effect of enhancing metabolism... Agent: Conwell LLC

20070225354 - Use of dihydrolipoamide for enhancing physical performance: A method of decreasing fat and adipose tissue, reducing appetite and increasing alertness in humans comprises administering dihydrolipoamide in a daily dosage between about 300 and 2000 mg. Dihydrolipoamide may be administered once per day or in multiple doses, either alone or in combination with other compounds and mixtures.... Agent: Miller, Canfield, Paddock And Stone P.L.C C/o Robert Kelley Roth

20070225356 - Preventive and/or therapeutic agent for chronic sinusitis: m

20070225359 - Dimeric compounds and their use as anti-viral agents: The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; and n is an integer from 10 to 18 or a pharmaceutically acceptable derivative thereof, methods for their preparation, pharmaceutical formulations containing them or their use in... Agent: Foley And Lardner LLP Suite 500

20070225358 - Dimeric compounds and thier use as anti-viral agents: The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; X is CONH, NHCO or O; n is an integer from 2 to 6; and Y is C2-C9 alkyl C3-8 cycloalkyl, C1-C4 alkoxyalkyl, an amino acid or... Agent: Foley And Lardner LLP Suite 500

20070225357 - Formulation for stimulating hair growth: The present invention is directed to a topical formulation comprising the Compound 6-[[(3S,4R)-3,4-dihydro-3-hydroxy-6-[(3-hydroxyphenyl)sulfonyl)-2,2,3-trimethyl-2H-1-benzopyran-4-yl]oxy]-2-methyl-3(2H)-pyridazinone in a formulation comprising at least one pharmaceutically acceptable carrier. Particularly, the formulation may be used to promote hair growth, including alleviating alopecia.... Agent: Warner-lambert Company

20070225360 - Anti-aging composition containing phloretin: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the... Agent: L'oreal Usa/ Patent Department

20070225361 - Dimeric compounds and their use as anti-viral agents: The invention relates to compounds of general formula (I), in which: R is an amino or guanidino group; R2 is acetyl or trifluoroacetyl; n and q are either the same or different and selected from 0, 1 or 2; and X is an optionally substituted phenyl, optionally substituted naphthyl or... Agent: Foley And Lardner LLP Suite 500

20070225362 - Compounds, compositions and methods for the treatment of amyloid diseases such as systemic aa amyloidosis: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed... Agent: Proteotech, Inc.

20070225363 - Methods and agents for inhibiting dynamin-dependent endocytosis: There are disclosed methods for inhibiting dynamin-dependent endocytosis in cells comprising treating the cells with an effective amount of a compound of formula (I), or a dimeric tyrphostin, physiologically acceptable salt, or prodrug thereof. Compounds useful in the methods described are also provided. The inhibition of dynamin-dependent endocytosis of cells... Agent: Edwards Angell Palmer & Dodge LLP

20070225364 - Use of bismuth subgallate and borneol in treating melanoma: A new use of bismuth subgallate and borneol for treating melanoma by the reduction of the number of melanoma cells and/or the inhibition of the proliferation of melanoma cells is provided. A use of bismuth subgallate and borneol for inhibiting the migration of melanoma cells is also provided.... Agent: Ladas & Parry

20070225365 - Cetp inhibitors: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused... Agent: Merck And Co., Inc

20070225366 - Levodopa prodrug mesylate, compositions thereof, and uses thereof: (2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070225367 - Composition for beneficially influencing alzheimer's disease and/or for alzheimer's prophylaxis: The invention relates to a composition for Alzheimer's prophylaxis and/or for therapeutic treatment of pre-existing symptoms of the type of Alzheimer's disease comprising a mixture of VLCFA3, in particular based on montan waxes and/or derivatives thereof or Guerbet acids or the corresponding components of carnauba wax, shellac or policosanols or... Agent: Clariant Corporation Intellectual Property Department

20070225368 - Therapy for multiple sclerosis: The invention relates to a method of ameliorating multiple sclerosis and/or the symptoms of multiple sclerosis in a mammal, which comprises administering or having self administered to the mammal an effective amount of (a) cetyl myristate or (b) cetyl myristate and cetyl palmitate. In preferred embodiments the mode of administration... Agent: Jacobson Holman PLLC

20070225369 - Ophthalmic composition for treating tear dysfunction: There are provided an ophthalmic composition that comprises 3-hydroxybutyric acid and/or salts thereof as active ingredients and is used to prevent desiccation of eyes and an ophthalmic composition that is used to treat tear dysfunction. By use of the ophthalmic compositions of the present invention, desiccation of the eyes can... Agent: Birch Stewart Kolasch & Birch

20070225370 - Nutritional compositions and methods: The invention is an anti-inflammatory composition comprising a mixture comprising two components, a first component rich in EPA and a second component rich in GLA. The first component is a mixture comprising EPA and preferably DHA comprising at least 35% EPA, preferably 50% EPA and more preferably 60% or more... Agent: Foothill Law Group

20070225371 - Dermatological composition containing alkyl ureas: This invention relates to a method for topically treating dermal disorders employing a composition comprising a mixture of urea and a safe and effective amount of an alkyl urea in a therapeutically effective ratio. The urea and alkyl urea are blended with a carrier suitable for topical application to dermal... Agent: Jerry Zhang

20070225372 - Amides as bace inhibitors: The present invention provides BRACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.... Agent: Eli Lilly & Company

20070225373 - Zn2motif-tethered short-chain fatty acids as a novel class of histone deacetylase: Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. One hydroxamate-tethered phenylbutyrate compound, N-hydroxy-4-(4-phenylbutyrylamino)-benzamide (HTPB), displayed nM potency in inhibiting HDAC activity. Exposure of several cancer cell lines to HTPB at sub-μM concentrations showed reduced cell proliferation accompanied by histone hyperacetylation and elevated p21WAF/CIP1 expression, hallmark features associated with intracellular... Agent: Calfee Halter & Griswold, LLP

20070225374 - Hydroxypropyl amides for the treatment of alzheimer's disease: The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070225375 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake... Agent: Darby & Darby P.C.

20070225376 - Medicinal agent: Medicine and pharmacology, in particular a medicinal agent exhibiting anti-tumoral and immunomodulatory actions and including a tri-p-amino-thiphenyl-chlormethan tetramethylated, pentamethylated or hexamethylated derivative, the mixtures thereof or the combination thereof with dextrin. The agent of this invention exhibits a high activity and a reduced side effect.... Agent: Pauley Petersen & Erickson

20070225377 - Bridged ring structures as pharmaceutical agents: The present invention is directed to 1α,25-dihydroxyvitamin D3 mimics which modulate the vitamin D receptor (VDR). The invention is further directed to pharmaceutical compositions and methods for the treatment, prevention or amelioration of one or more symptoms of disease or disorder related to the activity of the vitamin D receptor... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20070225378 - Menthol dearivative and cooling agent composition comprising the same: The invention relates to innovative menthol derivatives which are represented by the general formula (I) below and are excellent in a cooling effect and cool retaining effect, cooling agent compositions comprising the menthol derivatives, and sensory stimulation agent compositions containing the cooling agent compositions, as well as fragrance compositions, beverage... Agent: Mcdermott Will & Emery LLP

20070225379 - Transdermal delivery of systemically active central nervous system drugs: The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the Central Nervous System (CNS) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient.... Agent: Winston & Strawn LLP Patent Department

20070225380 - Parakeratosis inhibitor and skin preparation for external use: To provide a parakeratosis inhibitor, pore reducing agent and skin roughness preventing/ameliorating agent that exhibit capabilities of parakeratosis inhibition, pore reduction, skin roughness prevention/amelioration, etc., and further provide a skin preparation for external use having these capabilities. There are provide a parakeratosis inhibitor and a pore reducing agent each comprising... Agent: Snider & Associates

20070219127 - Cyclosporin a compositions: A composition comprising cyclosporin A and a nonaqueous, physiologically acceptable liquid carrier, said composition being suitable for topical administration to an eye of a mammal is disclosed herein. Methods of treating disease related thereto are also disclosed.... Agent: Allergan, Inc.

20070219160 - Process tolerant starch composition with high total dietary fiber content: The present invention relates to a starch composition with high total dietary fiber (TDF) that retains its TDF upon processing. In particular, over 50% of such fiber is retained upon extrusion processing. Such starch is useful in the manufacture of high fiber food products, including extruded products such as breakfast... Agent: National Starch And Chemical Company

20070219117 - Bidentate motif and methods of use: e

20070219116 - Follicle stimulating hormone superagonists: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070219119 - Method of treatment of tendonitis by administration of streptolysin o: The invention provides a method for administering streptolysin O for treatment of various conditions including connective tissue disorders, reproductive fibroses and conditions mediated by the CD44 receptor. The invention also provides methods for protecting nerve cells from the effects of neurotoxic agents by the administration of streptolysin O.... Agent: Marshall, Gerstein & Borun LLP

20070219120 - Methods for treating inflammatory disease by administering aldehydes and derivatives thereof: A method is disclosed for treating inflammatory disease in an animal in need thereof by administering to the animal a pharmaceutical composition containing an anti-inflammatory effective amount of an organic aldehyde compound or a derivative thereof in a pharmaceutically acceptable vehicle.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070219115 - Pharmaceutical uses of bisphosphonates: A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a chemotherapeutic agent selected from the group consisting of: taxol, a derivative thereof and letrozole, followed sequentially by an effective amount of a bisphosphonate. The invention further provides a method... Agent: Novartis Corporate Intellectual Property

20070219114 - Preventives or remedies for hepatopathy: The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of... Agent: Hunton & Williams LLP Intellectual Property Department

20070219118 - Therapeutic methods for nucleic acid delivery vehicles: It has been found that certain synthetic vectors and nucleic acid sequences that encode viral genomic sequences can, for example, be administered to a subject repeatedly as a vehicle for effectively delivering one or more therapeutic nucleic acid molecules or polypeptides to a cell or tissue. Accordingly, the disclosed nucleic... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070219121 - Vasodilator pharmaceutical preparation and health food composition: This invention provides a novel material having a vasodilator action thereby suppressing or ameliorating various human diseases and disorders. A composition comprising, as an active ingredient, peptides obtained by hydrolyzing proteins such as proteins derived from a seaweed selected from layer, wakame, edible brown algae, sea tangle, chlorella and spirulina,... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070219122 - Modified triple-helix forming oligonucleotides for targeted mutagenesis: High affinity, chemically modified triplex-forming oligonucleotides (TFOs) and methods for use thereof are disclosed. TFOs are defined as triplex-forming oligonucleotides which bind as third strands to duplex DNA in a sequence specific manner. Triplex-forming oligonucleotides may be comprised of any possible combination of nucleotides and modified nucleotides. Modified nucleotides may... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070219126 - Class of bioactive glycoprotein: The invention relates to a bioactive chemical composition, more specifically to proteins and can be used in medicine, veterinary and cell biology. The invented glycoproteins are extracted with the help of isoelectric focusing from intercellular space of tissues taken from different organs, blood serum and bile of the vertebrates (human... Agent: Jacobson Holman PLLC

20070219124 - Lipopeptide compositions: The invention relates to a pharmaceutical composition comprising as an active agent a lipopeptide in a physiologically effective dose and a cyclodextrin or a cyclodextrin derivative.... Agent: Mayer & Williams PC

20070219125 - Novel thrombospondin-1 polynucleotides encoding variant thrombospondin-1 polypeptides and methods using same: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and phamaceutical compositions which can be used to treat various disorders such as cancer and retinopathies, using the polypeptides and polynucleotides of the present invention.... Agent: Staas & Halsey LLP

20070219123 - Selective n-acylation of a82846 glycopeptide analogs: The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.... Agent: Merchant & Gould PC

20070219132 - Black bear parathyroid hormone and methods of using black bear parathyroid hormone: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a... Agent: Michael Best & Friedrich, LLP

20070219133 - Cd52 optimized fc variants and methods for their generation: The present invention relates to CD52 optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20070219131 - Compositions capable of facilitating penetration across a biological barrier: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.... Agent: Fish & Richardson PC

20070219129 - Hsp90 decoy peptides and uses thereof: A method of inhibiting hsp90 association with eNOS in a patient, comprising the step of treating a patient with an effective amount of a pharmaceutical composition comprising an hsp90 decoy peptide.... Agent: Quarles & Brady LLP

20070219134 - Lymphatic zip codes in tumors and pre-malignant lesions: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.... Agent: Needle & Rosenberg, P.C.

20070219128 - Medical and health-care uses of pufferfish type i collagen extract and processes for producing said extract: The present invention relates to the use of pufferfish type I collagen extract as effective ingredient in the manufacture of medicaments and health-care foods for prevention and treatment of the following diseases, wherein the main chemical components and active components of the pufferfish type I collagen extract are natural pufferfish... Agent: Seed Intellectual Property Law Group PLLC

20070219135 - Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptide: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and PAI-1 or a PAI-1-related polypeptide, and the use thereof for treating bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department

20070219130 - Slurp-1 compositions and methods of use thereof: Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders. Also disclosed are compositions and methods for the treatment or prevention of skin pathologies. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. Antibodies generated against SLURP-1 and related proteins are... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070219136 - Methods and compositions for treating inflammatory disorders: The present invention provides methods and compositions for treating inflammatory disorders, e.g., asthma, lung inflammation or cancer.... Agent: Lahive & Cockfield, LLP

20070219138 - Compositions capable of reducing elevated blood urea concentration: The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse... Agent: Trask Britt

20070219137 - Novel potassium channel modulator peptide: A novel 13-residue peptide Mo1659 has been isolated from the venom of a vermivorous cone snail, Conus monile. HPLC fractions of the venom extract yielded an intense UV absorbing fraction with a mass of 1659 Da. De novo sequencing using both matrix assisted laser desorption and ionization and electrospray MS/MS... Agent: Birch Stewart Kolasch & Birch

20070219139 - Immune-modulating peptide: Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or... Agent: Baker Botts L.L.P.

20070219140 - Iap bir domain binding compounds: s

20070219141 - Plant materials extraction method: A process for preparing plant extracts is provided. Plant materials, including tropolones, lignins and polar molecules, are mixed with a liquid polar solvent to form an extraction mixture, which is maintained under extraction conditions effective to extract lignins, polar molecules and at least 50% of the tropolones into the polar... Agent: Klarquist Sparkman, LLP

20070219142 - Composition comprising a diuretic and/or cardiac glycosed for the treatment of dna viral infections of the eye: DNA viral infections of the eye are treated or prevented by the application of a composition comprising a diuretic and/or a cardiac glycoside dissolved in a water/ethanol solution wherein the level of the ethanol is adjusted to be acceptable to the eye.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20070219143 - Antiinflammatory lactones: Lactones of Formula (I) which are pharmaceutically active in diseases associated with inflammation.... Agent: Novartis Corporate Intellectual Property

20070219144 - Immunomodulatory saccharide compounds: Compounds comprising a saccharide molecule and a 5-deoxy-5-methylthio-xylofuranose (MTX) moiety or a 5-deoxy-5-methylsulfoxy-xylofuranose (MSX) moiety, and use of such compounds in methods for modulating inflammation and immune responses.... Agent: Fish & Richardson P.C.

20070219145 - Radiosensitizer: m

20070219146 - Synergistic pharmaceutical and/or neutraceutical flavanoid composition for management of diabetes mellitus: The present invention relates to a synergistic pharmaceutical and/or neutraceutical flavanoid composition for management of Diabetes Mellitus, said composition comprising polyphenol of concentration ranging between 85 to 95% (w/w) GAE, theobromine of concentration ranging between 1 to 5% (w/w), and moisture content ranging between 0.5 to 10% (v/w).... Agent: Pharmaceutical Patent Attorneys, LLC

20070219153 - Immunostimulatory activity of immune modulatory oligonucleotides (imotm) containing different lengths of palindromic segments: The invention provides a palindromic immune modulatory nucleic acid. The invention also provides methods for generating, enhancing and modifying the immune response caused by palindromic immune modulatory compounds used for immunotherapy applications... Agent: Keown & Zucchero, LLP

20070219152 - Inhibition of syk kinase expression: The present invention relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small interfering RNA (siRNA).... Agent: Nixon & Vanderhye, PC

20070219147 - Insect chymotrypsin and inhibitors thereof: The present invention relates generally to a novel chymotrypsin that exhibits resistance to a plant serine proteinase inhibitor. More particularly, the present invention provides a chymotrypsin which is up-regulated in the gut of Helicoverpa armigera and Helicoverpa punctigera insect larvae when fed the serine proteinase inhibitors of Nicotiana alata. The... Agent: The Mccallum Law Firm, P. C.

20070219151 - Methods and compositions for inhibiting the function of polynucleotide sequences: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous... Agent: Wyeth Patent Law Group

20070219154 - Methods for preventing and/or treating a cell proliferative disorder: The present invention relates to methods for preventing and/or treating the growth and/or metastasis of a cell proliferative disorder. In particular, the methods include use of a protease activated receptor-1 (PAR-1) inhibitor.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070219150 - Nerve cell differentiation inducer: The present invention provides a nerve cell differentiation inducing drug containing a Synoviolin expression inhibitor which is a useful drug for treatments of neural disorders, particularly Alzheimer's disease, Parkinson's disease, peripheral nerve disorders or spinal injury. As Synoviolin expression inhibitors, there are siRNA against gene coding Synoviolin (SEQ ID No.... Agent: Dickstein Shapiro LLP

20070219149 - Novel vaccine containing adjuvant capable of inducing mucosal immunity: The present invention provides an adjuvant that possesses a greater adjuvant potential than that of a conventional adjuvant, and that is capable of producing a protective reaction across different strains. This problem has been solved by the finding that a double-stranded RNA (for example, Poly(I:C)) unexpectedly exhibits the above capability... Agent: Barnes & Thornburg LLP

20070219148 - Small interfering rna specific to sub-units $g(a),$g(a)' and $g(b) of the kinase protein ck2,and the applications of the same: The invention relates to small interfering RNA specific to sub-units α, α and β of the kinase protein CK2, and to the applications of the same, especially for treating cancer and viral illnesses.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070219155 - Treating trinucleotide repeat conditions: This document provides methods and materials related to treating trinucleotide repeat conditions. For example, methods and materials for treating a trinucleotide repeat condition as well as methods and materials for identifying OGG1 polypeptide inhibitors that can be used to treat a trinucleotide repeat condition are provided.... Agent: Fish & Richardson P.C.

20070219157 - Complete nutrient medium for use as a cosmetic and cosmetic use thereof: A cosmetic composition contains an aqueous complex nutritive base comprising a plurality of amino acids, at least one vitamin, a plurality of assimilable organic components, and at least one inorganic salt. The cosmetic composition does not contain a biological extract of animal or cellular origin, or a living nourishing substrate.... Agent: Oliff & Berridge, PLC

20070219156 - Method of treatment for central nervous system injury: Injuries to the central nervous system, particularly spinal cord injuries, are treated by administering a purine nucleoside or analog to the patient and, optionally, electrically stimulating the site of injury.... Agent: Ice Miller LLP

20070219158 - External preparation for skin and cosmetic containing inositol derivative: The present invention discloses a skin external preparation which contains an inositol derivative in which an inositol and a saccharide are combined. The invention aims to provide the external preparation for skin that can be spread over skin without causing grain feeling and has excellent effects of giving sufficient moist... Agent: Sughrue Mion, PLLC

20070219159 - Cyclodextrin compositions and methods of treating viral infections: The present invention provides methods and therapeutic compositions for treating viral infections.... Agent: Alston & Bird LLP

20070219161 - Preparation process of oligoglycosaminoglycan, and reducing end glucuronic acid type oligochondroitin sulfate and pharmaceutical composition comprising the same: A sugar donor having a glucuronic acid or iduronic acid derivative at the reducing end and in which a leaving group is added to the reducing end hydroxyl group to be glycosylated and the other hydroxyl groups and the carboxyl groups are protected, is subjected to glycosylation reaction with a... Agent: Sughrue Mion, PLLC

20070219162 - Partially-fluorinated ethers, compositions and uses thereof, for long-term tamponade in the eye: The present invention provides a single high-purity liquid comprising a partially fluorinated ether liquid for use as a long-term tamponade agent. Compositions are directed to liquid tamponade agents consisting essentially of DFPE, or to agents comprising a soluble mixture of a partially fluorinated ether and either a silicone liquid (or... Agent: Wilmerhale/columbia University

20070219163 - Compounds active in sphingosine 1-phosphate signaling: e

20070219164 - Pharmaceutical compound and method: A new pharmaceutical compound for treating central nervous disorders, the compound comprising a therapeutically effective amount of valproic acid or pharmaceutically acceptable derivative thereof covalently bonded to myo-inositol. The invention also provides a composition, method for treating a patient and a method for obtaining the compound.... Agent: Norris, Mclaughlin & Marcus P.A. 18th Floor

20070219165 - Peptidomimetic inhibitors of psma, compounds comprising them, and methods of use: Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070219166 - Stereoselective method for the production of clopidogrel: m

20070219167 - Composition and method of treating hearing loss: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing... Agent: Howard & Howard Attorneys, P.C.

20070219168 - 19,26,27-trinor-1alpha,25-dihydroxyvitamin d3 compounds: Compounds of formula 1 are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups, and R1 and R2 have the definitions provided herein. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent: Foley & Lardner LLP

20070219169 - Pharmaceutical compositions comprising trimegestone: The invention concerns a pharmaceutical composition comprises trimegestone optionally associated with an oestrogen, characterized in that it comprises a buffer solution whereof the pH, when it is introduced in the composition, ranging essentially between 2 and 5.5. The invention also concerns the methods for making such a composition and the... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070219170 - Ophthalmic compositions comprising povidone-iodine: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070219173 - Ligands for nematode nuclear receptors and uses thereof: t

20070219172 - Selective testicular 11beta-hsd inhibitors for the treatment of hypergonadism associated disorders and modulation of fertility: Methods for modulating testosterone levels using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described.... Agent: Lahive & Cockfield, LLP

20070219171 - Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aquous vehicle: Transdermal spray formulations containing a pharmaceutically active agent and methods for administering the same are provided. The formulations comprise the pharmaceutically active agent, a VP/VA copolymer and a non-aqueous vehicle. The formulations further comprise an anti-nucleating agent to prevent recrystallization of the pharmaceutically active agent and a penetration enhancer to... Agent: Conley Rose, P.C.

20070219174 - Methods of treating cancer using hypofractionated radiation and texaphyrins: Described herein are methods of treating cancer by administering a therapeutically effective amount of at least one texaphyrin metal complex or a pharmaceutically acceptable derivative, and performing stereotactic radiosurgery to the patient. In some embodiments, at least one texaphyrin metal complex or a pharmaceutically acceptable derivative is administered while the... Agent: Wilson Sonsini Goodrich & Rosati

20070219175 - Controlled release pharmaceutical composition comprising an acid-insoluble and a bioadhesive polymer: Rapidly disintegrating oral controlled release pharmaceutical compositions and process for preparation of such compositions are provided. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions comprise at least one active ingredient, and a polymer system comprising... Agent: Ladas & Parry

20070219177 - Agent for treatment of cerebral ischemic diseases: (wherein R6 is hydroxy, etc., (1) n is 1, R11 is hydrogen and R5 is (alkyl of which one carbon atom is substituted by fluorine)-CH2— or (2) n is 0 or 1, R11 is hydrogen, etc., and R5 is alkyl, etc.) and a thrombolytic agent, preferably tissue plasminogen activator, as... Agent: Sughrue-265550

20070219176 - Viral polymerase inhibitors: h

20070219178 - Preventive or therapeutic agents for multiple sclerosis:

20070219179 - Indole derivative having piperidine ring: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a... Agent: Birch Stewart Kolasch & Birch

20070219181 - Multi-cyclic cinnamide derivatives: or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and... Agent: Birch Stewart Kolasch & Birch

20070219180 - Muscle relaxtion accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure: (wherein R3 represents a C1-C3 acyl group); X represents —CO— or —CH2—, and n represents an integer of 1 or 2.] Said muscular relaxation accelerating agent is the drug to make muscle relax to treat left ventricular diastolic dysfunction, angina pectoris and acute pulmonary edema, and improve blood flow of... Agent: Ostrolenk Faber Gerb & Soffen

20070219183 - Dihydropyrazolo[1,5-a]pyrimidine and dihydroimidazo[1,5-a]pyrimidine derivatives and methods of use thereof: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine and dihydroimidazo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a dihydropyrazolo[1,5-a]pyrimidine or a dihydroimidazo[1,5-a]pyrimidine derivative and methods for treating or preventing cancer, comprising administering to a subject in need thereof an effective amount of a dihydropyrazolo[1,5-a]pyrimidine or a dihydroimidazo[1,5-a]pyrimidine derivative.... Agent: Wyeth Patent Law Group

20070219182 - Keto lactam compounds and use thereof: The invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suited for treating diseases that respond to the modulation of the dopamine D3 receptor. The keto lactams have general formula (I), wherein: (a) represents a group of formulas... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070219184 - Method of increasing thymic output in hiv-negative patients by treatment with antiretroviral agents: A method of increasing thymic output in an HIV-negative patient, comprising the steps of (a) identifying a HIV-negative patient who is in need of increased thymic output and (b) supplying an effective amount of antiretroviral agent to the patient such that the patient has an increase in naïve T-cells.... Agent: Quarles & Brady LLP

20070219185 - Preventive or therapeutic agent for neuropathic pain: The present invention provides medicinal agents that are useful for the prevention or treatment of neuropathic pain which comprises as an active ingredient a β2 adrenoceptor stimulant. In addition, the present invention provides formulations for the prevention or treatment of neuropathic pain such as painful diabetic neuropathy, postherpetic neuralgia, trigeminal... Agent: Stuart D. Frenkel Frenkel & Associates, P.C.

20070219186 - Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof: The present invention relates to pyrazolo[1,5-a]pyrimidine derivatives, compositions comprising an effective amount of a pyrazolo[1,5-a]pyrimidine derivative and methods for treating or preventing cancer, comprising administering to a subject in need thereof an effective amount of a pyrazolo[1,5-a]pyrimidine derivative.... Agent: Wyeth Patent Law Group

20070219187 - Allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.... Agent: Edwards Angell Palmer & Dodge LLP

20070219188 - Oxadiazine derivatives: e

20070219189 - Mif-inhibitors: 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C3-8)cycloalkyl, (C1-4)alkyl(C3-8)cycloalkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.... Agent: Novartis Corporate Intellectual Property

20070219190 - Heterocyclic nf-kb inhibitors: 4

20070219193 - Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar: The present invention relates to novel alkylamine-substituted bicyclic aryl compounds, pharmaceutical compositions comprising the same, useful as modulators of PPAR, and methods for the treatment or prevention of disease.... Agent: Global Patent Group Attn: Ms Lavern Hall

20070219191 - 3-pyridinium methyl cephem compound: (wherein R1 and R2 are each independently hydrogen, optionally substituted amino lower alkyl, optionally substituted aminocycloalkyl, optionally substituted cyclic amino, or optionally substituted cyclic amino lower alkyl; R9 is hydrogen or lower alkyl, or R1 and R9 taken together with an adjacent N atom may form optionally substituted cyclic amino;... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070219192 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070219194 - Phenylalanine derivatives: The present invention provides phenylalanine derivatives that inhibit SH2 domain binding with a phosphoprotein. These derivatives include compounds of the formula: W—Y-(AA)n-Z wherein n is 0 to 15; Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, the phenyl ring having one or... Agent: Leydig, Voit & Mayer, Ltd.

20070219195 - Methods of inhibiting btk and syk protein kinases: Methods of inhibiting a tyrosine kinase wherein said tyrosine kinase is BTK or SYK comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula I are disclosed. The compounds are useful for treating auto-immune and inflammatory diseases.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070219196 - Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines: Imidazopyridine, imidazoquinoline, and imidazonaphthyridine compounds having an amide substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20070219197 - Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives: The present invention relates to new pyridine compounds, methods for their production, medicaments containing these compounds as well as their use, especially in the treatment of tumor conditions and/or as cytostatic agents or as immunosuppressive agents.... Agent: Scully Scott Murphy & Presser, PC

20070219198 - 11-beta hsd 1 inhibitors: This invention relates to inhibiting 11βHSD1.... Agent: Fish & Richardson P.C.

20070219199 - Use of sulfonanilides as agricultural and horticultural fungicide: Compounds of the formula (I), wherein Z represents C—R7 or N, and R represents alkyl that may be optionally substituted, alkenyl, alkynyl, cycloalkyl or alkoxycarbonylamino, are useful as agricultural and horticultural fungicides.... Agent: Frommer Lawrence & Haug

20070219200 - Prodrugs of heteroaryl compounds: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.... Agent: Townsend And Townsend And Crew, LLP

20070219201 - Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders: This invention relates to combinations of atomoxetine, and a 5HT1A receptor agonists, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from ADHD, related disorders, and other central nervous system diseases or disorders.... Agent: Warner-lambert Company

20070219202 - 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics: i

20070219206 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20070219203 - Arylalkylamino-substituted quinazoline analogues: Arylalkylamino-substituted quinazoline analogues are provided, of the Formula wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion... Agent: Edwards Angell Palmer & Dodge LLP

20070219204 - Pharmaceutically active ornitihine derivatives, ammonium salts thereof and methods of making same: The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of Nδ-acyl derivatives of Nα(4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability... Agent: Jones Day

20070219207 - Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups: e

20070219205 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20070219208 - Methods for treating cancer: It is disclosed here that HMG-CoA reductase inhibitors inhibit the proliferation and cause the death of breast cancer cells by inducing the expression of inducible nitric oxide synthase (iNOS) to promote intracellular nitric oxide formation, which the inventors found to be accomplished through the inhibition of protein geranylgeranylation. The disclosure... Agent: Quarles & Brady LLP

20070219210 - Amidopyrazole derivative: wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxy carbonyl group, a lower alkoxy group, a lower... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070219211 - Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (scd): Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise, for example, administering to a mammal in need thereof a compound of formula (I): where x, y, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7,... Agent: Seed Intellectual Property Law Group PLLC

20070219212 - Pyranouidole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease: The invention is directed to novel pyranoindole derivatives and analogs as well as compositions containing the same and to the use thereof for the treatment, prevention or inhibition of viral infections and associated diseases caused by the Hepatitis C virus.... Agent: Patrick J Hagan Dann Dorfman Herrell And Skillman

20070219209 - Piperazine derivatives of alkyl oxindoles: The present invention is concerned with new indol-2-one derivatives of the general Formula (I). The new compounds are useful for the treatment or prevention of the disorders of the central nervous system or the cardiovascular system.... Agent: Birch Stewart Kolasch & Birch

20070219214 - Dual nk2/nk3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation: e

20070219213 - Use of adrenergic n-phenylpiperazine antagonists, pahrmaceutical compositions containning them, and methods of preparing them: The present invention describes phenylpiperazinyl alpha adrenergic antagonists that corresponds to the formula (I) which selectively act on the alpha 1A/alpha 1D subtypes, where its selectivity index in comparison to alpha 1B subtype is, at minimum, 1700 for the alpha 1A subtype and 10000 for the alpha 1 D subtype,... Agent: Powell Goldstein LLP

20070219215 - Thioamides and salts thereof and cytokine production inhibitors containing both: wherein A is N, NO, C—NO2 or C—CN; Hal is a halogen; M1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, amino, O, S, SO or SO2; M2 is amino, O, S or a single bond; R1 is a halogen, alkyl or the like; each of R2, R3, R4 and... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070219216 - 1-alkylpiperazinyl-pyrrolidin-2,5-dione derivatives as adrenergic receptor antagonists: This invention relates to α1a and/or α1d adrenergic receptor antagonists of formula 1 Compounds disclosed herein can function as α1a and/or α1d adrenergic receptor antagonists and can be used for the treatment of diseases or disorders mediated through α1a and/or α1d adrenergic receptors. Compounds disclosed herein can be used for... Agent: Ranbaxy Inc.

20070219217 - Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd: i

20070219218 - Compounds for the treatment of inflammatory disorders:

20070219219 - Methods of preparation and resolution of e/z isomers of vinylfuro[2,3-d]pyrimidine and their biological activities and related compositions and methods of treatment: Stereoselective methods for preparing the individual isomers, E- and Z-2,4-substituted-5-vinylfuro[2,3-d]pyrimidine and pharmaceutically acceptable salts, solvates, and prodrugs thereof using selective synthetic conditions are presented. This class of pyrimidine compounds function as receptor tyrosine kinase inhibitors during angiogenesis and resists the development of new blood vessels in tumors. These compounds also... Agent: Eckert Seamans Cherin & Mellott

20070219221 - Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists: The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical... Agent: Cv Therapeutics, Inc.

20070219220 - Pyrazolopyrimidinethione derivatives, salts and solvates thereof, preparation methods and use thereof: The present invention disclosed the pyrazolopyrimidinethione derivatives, salts and solvates thereof, preparation methods and use thereof. The pyrazolopyrimidinethione derivatives according to the present invention possess the structure of general formula I, wherein, R1, R2, R3, and R4 represent alkyl, alkenyl, or aryl; R5 represents hydrogen, alkyl, alkenyl, alkoxy, cycloalkyloxy, aryl,... Agent: Sughrue Mion, PLLC

20070219223 - Compositions and methods for treating respiratory disorders: Methods and compositions for treating and preventing respiratory disorders are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of a pharmaceutically acceptable salt of an A1 adenosine receptor antagonist, particularly 1-hydroxy-2-naphthoic acid salts or 3-hydroxy-2-naphthoic acid salts, more particularly a 1-hydroxy-2-naphthoic acid salt... Agent: Alston & Bird LLP

20070219222 - Methods and compositions for treating pain: The present application relates to compounds and methods for treating pain, incontinence and other conditions.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070219224 - Compositions and methods relating to pyrimidine synthesis inhibitors: Provided herein are compositions comprising a pyrimidine synthesis inhibitor and a pharmaceutically acceptable carrier Such compositions can be used in methods of increasing Na+ dependent fluid clearance by a pulmonary epithelial cell; of treating a pulmonary disease in a subject; of reducing one or more symptoms or physical signs of... Agent: Fish & Richardson P.C.

20070219225 - Pharmaceutical compositions for the prevention and treatment of atherosclerosis: o

20070219226 - Methods for treating sarcopenia with a growth hormone secretagogue: The present invention relates to methods for treating sarcopenia with a growth hormone secretagogue.... Agent: Feldmangale, P.A.

20070219227 - Prodrugs of benzoquinolizine-2-carboxylic acid: The instant invention relates to novel prodrugs of optically pure benzoquinolizine-2-carboxylic acid and pharmaceutical compositions that include the prodrugs. In particular, the present invention relates to the sulfonic acid salts of L-alanine and L-valine prodrugs of S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. The compounds and compositions of the invention can be used to treat... Agent: Bio Intellectual Property Services (bio Ips) LLC

20070219228 - Aryl substituted imidazonaphthyridines: Imidazonaphthyridine ring systems substituted with an aryl substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20070219232 - Chemical compounds: R11 is C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, or C(O)NR6R7; X is carbon or nitrogen; n is 1 or 2; to processes for their preparation, to pharmaceutical compositions containing them and to their use in the... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070219229 - Pyrrolopyridine derivatives: The present invention relates to novel pyrrolopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070219230 - Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof: The present invention provides novel pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Sughrue Mion, PLLC

20070219231 - Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof: This invention discloses novel quinolonecarboxylic acid derivatives, pharmaceutically acceptable salts or hydrates thereof, and their preparation methods and medical uses. The compounds in this invention show potent antibacterial activity against broad-spectrum pathogenic bacteria, with favorable pharmacokinetics and very low toxicity. The quinolinecarboxylic acid derivatives, which possess a hydrogen atom or... Agent: Morrison & Foerster LLP

20070219233 - Substituted indoles and their use as integrin antagonists: i

20070219235 - Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors: The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070219234 - Thienopyridine derivatives: e

20070219237 - Chromane derivatives: R1, R2, R3, R4, R5, R6, R7, R8 A and B are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such... Agent: Pfizer Inc.

20070219236 - Dialkoxy-imidazopyridines derivatives: ,

20070219238 - Fungicidal mixtures:

20070219240 - N-substituted-azacyclylamines as histamine-3 antagonists: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.... Agent: Wyeth Patent Law Group

20070219239 - Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents: The present application provides nitrogen-containing heterocycle derivatives that are antiviral compounds that may be useful in the treatment of a viral infection. Compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) may be administered to a subject for antiviral therapy or prophylaxis.... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070219241 - Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation: Compounds identified by the general formula (I) are used for the treatment of Alzheimer's disease.... Agent: Marshall, Gerstein & Borun LLP

20070219243 - Method for improving the pharmacokinetics of hiv integrase inhibitors: The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor.... Agent: Viksnins Harris & Padys Pllp

20070219242 - Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc): Novel quinoline inhibitors of retroviral integrase, particularly HIV-1 integrase. The quinoline inhibitors are oxoquinolines that can be used for preventing or treating AIDS or HIV infection in a subject.... Agent: Klarquist Sparkman, LLP

20070219244 - Histone deacetylase inhibitors as therapeutics for neurological diseases: v

20070219245 - Method of use for substituted dipiperidine ccr2 antagonists:

20070219246 - Dihydrobenzothiophenes: Compounds of the formula (I) in which W, R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070219247 - Medicament: This invention provides the use of the compound [2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)]-([2S,3S]-2-phenyl-piperidin-3-yl)-amine, pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing them for the manufacture of a medicament for the treatment or prevention of Posttraumatic Stress Disorder (PTSD).... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070219248 - Salt of oxalic acid with -[4[2-(n-methyl-n-(2-pyridyl)-amino)ethoxy]benzyl]thiazolidin-2,4- dione and a method of its preparation and its use: The salt of oxalic acid with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)-ethoxy]-benzyl]-thiazolidin-2,4-dione of formula III including its tautomers and solvates. The method of preparation of the salt of oxalic acid with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)-ethoxy]thiazolidin-2,4-dione consists in a reaction of 5-[4-[2-(N-methyl-N-(2-pyridyl)-amino)ethoxy]benzyl]thiazolidin-2,4-dione of formula I with oxalic acid, the reaction being carried out in a solution in organic solvent... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070219249 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of formula: wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070219251 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: m

20070219250 - Pharmaceutical compositions of nateglinide: The present invention relates to pharmaceutical compositions comprising nateglinide in combination with a surfactant, and processes for their preparation.... Agent: Ranbaxy Inc.

20070219252 - Vla-r antagonists: Compounds of Formula (I) are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's... Agent: Merck And Co., Inc

20070219255 - Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain: m

20070219253 - Decongestant / antihistaminic / expectorant compositions: Compositions consisting essentially of phenylephrine tannate, pyrilamine tannate, and guaifenesin which are effective when administered orally for the symptomatic relief of cough and nasal congestion associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis are disclosed.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070219254 - Therapeutic compounds: pyridine n-oxide scaffold: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: White & Case LLP Patent Department

20070219256 - Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents: m

20070219257 - Wnt pathway antagonists: Aromatic compounds for treating various diseases and pathologies are disclosed. The methods use of such compounds are also provided. Accordingly, the present invention makes available methods and compositions for inhibiting aberrant growth states in cells having Wnt receptors.... Agent: Dla Piper US LLP

20070219259 - New 3-phenylpropionic acid derivatives: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO-C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or... Agent: Darby & Darby P.C.

20070219258 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: e

20070219261 - Anthranilamide and 2-amino-heteroarene-carboxamide compounds:

20070219262 - Omega-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists:

20070219263 - Metronidazole/azelaic acid compositions for the treatment of rosacea: Pharmaceutical compositions useful for the treatment of rosacea, in particular for the treatment of the inflammatory component thereof, contain synergistically effective amounts of each of (i) metronidazole or derivative or salt thereof and (ii) azelaic acid or derivative or salt thereof.... Agent: Buchanan, Ingersoll & Rooney PC

20070219264 - Induction of immune tolerance: a

20070219265 - Substituted gamma lactams as therapeutic agents:

20070219266 - N-acylated-3-(benzoyl)-pyrrolidines as 11-beta-hsd1 inhibitors useful for the treatment of metabolic disorders: The use of compounds of formula (I): wherein variable groups are defined within; in the manufacture of medicaments for use in the inhibition of 11βHSD1, processes for making them, certain compounds within the definition of the formula (I) and pharmaceutical compositions comprising them are described.... Agent: Morgan Lewis & Bockius LLP

20070219267 - Product for treating warts: The subject invention is product for amelioration, removal, or other treatment of warts comprising a combination of vinegar and vitamin E, which product may be emulsified in a cream form or a liquid form, or other appropriate form, wherein it is contemplated that said resultant substance be applied directly to... Agent: George R. Royer

20070219268 - Anti-cancer activity augmentation compounds and formulations and methods of use thereof: The field of the present invention comprises pharmaceuticals and pharmaceutical treatments, including, for example, (i) compounds and formulations which cause the augmentation of anti-cancer activity (i.e., by enhancement of the lethal cytotoxic action in stimulatory [inducing oxidative stress] and/or depletive [decreasing anti-oxidative capacity] manner) of chemotherapeutic agents, in a selective... Agent: Scott A. Whitaker, Ph.d., J.d. -sr. Intellectual Property Counsel

20070219269 - Novel aconitase: A bacterial protein which converts 2-methyl citrate to 2-methyl isocitrate is a previously unknown target for antibacterial agents. The protein of this activity is associated with mucoid bacteria and inhibitors of production or activity of this protein in combination with propionic acid mitigate the virulence of these bacteria.... Agent: Morrison & Foerster LLP

20070219270 - Medium chain fatty acids applicable as anti-microbial agents: The present invention relates to the use of medium chain fatty acids (MCFA), chosen from the group consisting of caproic acid (C6), caprylic acid (C8) and capric acid (C10), salts, derivatives or mixtures thereof, in a total amount by weight comprised between 0.01% and 5% for inhibiting the growth of... Agent: Amster, Rothstein & Ebenstein LLP

20070219271 - Pharmaceutical compositions containing pufa and at least one of an immunosuppressive agent or an antineoplastic agent: Polyunsaturated fatty acid (“PUFA”) or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacologically acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically... Agent: Bacon & Thomas, PLLC

20070219272 - Novel method and compositions for treatment of tinnitus: The invention is related to a novel method and compositions for the treatment or alleviation of tinnitus. The compositions which are to be administered locally into the middle ear cavity, or orally, contain a therapeutically effective and physiologically acceptable amount of lithium. The treatment may be continuous or intermittent.... Agent: Dinsmore & Shohl, LLP

20070219273 - Enhanced activity alcohol-based antimicrobial compositions: Antimicrobial compositions which can be used wherever disinfecting compositions are needed, such as in a hospital, healthcare industry, workplace, recreational facility, home or similar environment. The antimicrobial compositions are particularly useful as a topical application for a substrate, such as skin and can be used as a hand sanitizer or... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20070219274 - (r)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted... Agent: Pfizer Inc.

20070219275 - Use of benzophenone uv filters for preventing tanning: The invention describes the use of organic UV filters of formula (I) wherein R, and R2, 'independently from each other are hydrogen, C1-C2, alkyl, C2-C10 alkenyl, C3 C,ocycloalkyl, C3-C10cycloalkenyl, or R, and. R2 togethér with the nitrogen atom to which they are bonded can form a 5- or 6-membered ring;... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070219276 - Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer: Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal... Agent: Wilson Sonsini Goodrich & Rosati

20070219277 - Small molecules used to increase cell death: The invention features methods for increasing cell death. The invention also features compounds used to increase cell death. The invention further features methods for identifying compounds that increase cell death.... Agent: Clark & Elbing LLP

20070219278 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists: wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity,... Agent: Theravance, Inc.

20070213293 - Rnai therapeutic for respiratory virus infection: Double stranded siRNA molecules for combating a respiratory virus, wherein the strands of an siRNA molecule may be from about 15 to about 60 nucleotides, and uses thereof. One strand of an siRNA molecule can be a nucleic acid sequence identical to a conserved site, or a variant thereof, within... Agent: Nastech Pharmaceutical Company Inc

20070213300 - Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors: u

20070213302 - Cannabinoid receptor antagonists/inverse agonists useful for treating obesity: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.... Agent: Vance Intellectual Property, PC

20070213256 - Novel genes and proteins encoded thereby: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, proteins encoded thereby, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, and methods for treating a cell using such nucleic acids or proteins.... Agent: Olson & Hierl, Ltd.

20070213255 - Novel hyaluronan-binding proteins and encoding genes: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070213254 - Remedy for diabetic neuropathy comprising gelatin gel as carrier: The present invention provides a therapeutic agent for diabetic neuropathy capable of more effectively treating diabetic neuropathy, wherein a basic fibroblast growth factor is carried on a gelatin gel.... Agent: Leydig Voit & Mayer, Ltd

20070213253 - Synuclein mutant having aggregation-inhibitory activity: Disclosed is a mutant human α-synuclein with decreased ability of forming aggregation. The mutant human α-synuclein of the invention is able to inhibit aggregation of the wild type human α-synuclein, Ala53Thr mutant human α-synuclein or Ala50Pro mutant human α-synuclein, thus is useful for investigation of pathology and treatment of Parkinson's... Agent: Birch Stewart Kolasch & Birch

20070213257 - Compositions and methods for complexes of nucleic acids and peptides: Compositions and methods are provided for producing a complex between a double stranded (ds) nucleic acid and a peptide, comprising: a. solubilizing the nucleic acid in an aqueous solution; b. solubilizing the peptide in an aqueous solution; and c. mixing the solubilized ds nucleic acid and the solubilized peptide in... Agent: Nastech Pharmaceutical Company Inc

20070213258 - Endotoxin adsorbent, and method for removing endotoxin using the same: m

20070213259 - Method for stabilizing blood pressure in hemodialysis subjects: The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.... Agent: Mandel & Adriano

20070213260 - Novel process for the preparation of cyclosporin derivatives: The invention concerns a novel method for preparing an intermediate polyanion for preparing cyclosporin derivatives by treating a cyclosporin with a hexamethyldisilazane metal salt, optionally in the presence of a metal halide. The treated cyclosporin has one or several free hydroxy groups and/or non-methylated nitrogen atoms in position a and/or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070213261 - Asthma preparation: A preventive or therapeutic agent for asthma, comprising HGF or its salt as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070213271 - Composition and method for treating hiv infection: Methods for inhibiting HIV propagation and treating HIV infection are provided which include administering to cells infected with HIV a compound capable of inhibiting viral budding from the infected host cells. The methods are especially useful in treating HIV infection and in treating and preventing AIDS.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070213268 - Eg-vegf nucleic acids and polypeptides and methods of use: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which... Agent: Merchant & Gould PC

20070213275 - Formulations for ecallantide: Disclosed herein are new formulations for ecallantide which are stable at room temperature and useful as pharmaceutical formulations.... Agent: Fish & Richardson PC

20070213265 - Kunitz-type sequences and polypeptides: The invention described herein provides novel human Kunitz-type protease inhibitors; nucleic acids encoding such inhibitors; vectors and host cells comprising such nucleic acids; compositions comprising such inhibitors, cells, and/or nucleic acids; methods of producing such inhibitors, nucleic acids, vectors, compositions, and cells; and methods of inducing, promoting, and/or enhancing a... Agent: Novo Nordisk, Inc. Patent Department

20070213263 - Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis: We have surprisingly discovered that adiponectin regulates angiogenesis and have shown that adiponectin is an effective agent at treating cardiac disorders. As a result of this discovery, the present invention provides methods for treatment of cardiac disorders and methods for stimulation of angiogenesis in tissues using adiponectin. In one preferred... Agent: Ronald I Eisenstein Nixon Peabody

20070213266 - Methods for using and identifying modulators of delta-like 4: In certain embodiments, this present invention provides methods of identifying and using agonists and antagonists of Delta-like 4 (Dll4) signaling.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070213262 - Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment: A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. Moreover, the mixture may... Agent: Moore & Van Allen PLLC

20070213264 - Neuregulin variants and methods of screening and using thereof: The present invention provides polypeptide variants of neuregulin-1β (NRG-1β) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1β and methods of using polypeptide variants of NRG-1β for treating diseases.... Agent: Jones Day

20070213274 - Novel genes and markers associated with high-density lipoprotein-cholesterol (hdl-c): This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in the regulation of human high density lipoprotein (HDL) and pharmaceutical agents and other therapies affecting this. This invention discloses methods for the treatment and prevention of low HDL states and diseases to prevent... Agent: Birch Stewart Kolasch & Birch

20070213270 - Peptide yy formulations having increased stability and resistance to microbial agents: Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY (PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) wherein the formulations have increased resistance to microbial contamination and is comprised of a Y2 receptor-binding peptide, water, a cyclodextrin and sodium benzoate.... Agent: Nastech Pharmaceutical Company Inc

20070213267 - Peptides and calcium regulation in mammalian cells: Calcium channels in a variety of tissues may contain different subunits, including several different γ (gamma) subunits. We report studies regarding structural features of certain gamma subunits, for example the N-terminal first transmembrane domain (TM1) of the subunit γ6. We disclose that certain structural motifs, for example a GxxxG-like structural... Agent: Greenlee Winner And Sullivan P C

20070213272 - Transmucosal administration agent containing pth: There is provided a method for inhibiting symptoms such as nausea at administration of PTH, and a pharmaceutical composition capable of inhibiting the same. The pharmaceutical composition for transmucosal administration contains hPTH or a derivative thereof and the composition is administered for purpose of increasing bone mass or bone density,... Agent: Birch Stewart Kolasch & Birch

20070213273 - Vertebrate embryonic pattern-inducing proteins, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070213269 - Zinc finger binding domains for tnn: Polypeptides that contain zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula TNN are provided. Compositions containing a plurality of polypeptides, isolated heptapeptides possessing specific binding activity, polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides, compositions and polynucleotides are also provided.... Agent: Catalyst Law Group, Apc

20070213276 - Epithelial cell growth promoter: It is intended to provide a novel oligopeptide which can be relatively easily produced, has not only a hair growth-stimulating effect but also an effect of promoting the growth of epithelial cells (for example, skin regeneration) and can easily pass through the horny layer to thereby reach the desired target... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070213277 - Compositions and methods for enhancing drug delivery across and into ocular tissues: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery... Agent: Morrison & Foerster LLP

20070213278 - Arrays with cleavable linkers: The invention provides arrays of molecules where the molecules (e.g., glycans) are attached to the arrays by cleavable linkers. The invention also provides methods for using these arrays, methods for identifying the structural elements of molecules bound to these arrays by using the cleavable linkers, especially the structural elements that... Agent: Frommer Lawrence & Haug

20070213279 - O6-alkylguanine-dna alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs: Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the... Agent: Leydig, Voit & Mayer, Ltd.

20070213280 - Steroidal saponins compound, the process for producing the same and the use thereof: wherein, R1=β-D-glucose; R2=straight or bifurcate sugar chains; R3═H or CH3. In this invention, by various ways of separation, the steroidal saponins compound with chemical structure of (I) or (II) could be extracted, synthesized or semi-synthesized process from traditional Chinese medicine and natural products. Oral dosage drug or non-oral dosage drug... Agent: GlobalIPServices

20070213281 - Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers: The present invention relates to identification of Oroxylum indicum, Indian medicinal plant as a rich source for flavanoid compounds. Mucoprotective and antigastric ulcer properties in the flavone class of compounds isolated therefrom have been identified along with a flavanoids mixture in substantial yields from hexane and acetone extracts. The hexane... Agent: Nixon & Vanderhye, PC

20070213282 - Peroxisome proliferator-activated receptor (ppar) activator, and drugs, supplements, functional foods and food additives using the same: The present invention provides a peroxisome proliferator-activated receptor (PPAR) activator, which is free from the problem of side effects, can be taken over a long term and has no characteristics taste. Nobiletin is employed as a PPAR activator. Nobiletin has an excellent PPAR activity and has an excellent adiponectin secretion-promoting... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070213283 - Macrolides substituted at the 4\"-position: e

20070213288 - Adenoviral vector capable of infecting tumor cells and eliminating the function of stat3: An adenoviral vector which expresses a dominant negative form of Stat3 called Stat3-EVA for the treatment of non-small cell lung carcinoma. This construct has two mutations in the DNA binding site of Stat3 which prevents binding to DNA but has no effect on tyrosine phosphorylation or dimerization.... Agent: Smith Hopen, Pa

20070213292 - Chemically modified oligonucleotides for use in modulating micro rna and uses thereof: This invention relates generally to chemically modified oligonucleotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonucleotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070213286 - Inhibitors of dynein or lissencephaly 1, and methods of using same for treatment of neuronal disorders: The invention provides antagonists and agonists of dynein mediated activity, for example specific inhibitory RNAs and dominant negative cDNAs which function as antagonists of LIS1 and dynein, and compositions comprising such antagonist and agonists. Provided are also methods for treating unwanted cell proliferation of neural progenitor cells such as cancers... Agent: Wilmerhale/columbia University

20070213289 - Method for purifying plasmid dna: This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatogragphy, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous... Agent: Wiley Rein LLP

20070213284 - Method of selecting targets for gene silencing by rna interference: The invention relates to the selection of target regions of RNA transcripts for specific down-regulation of gene expression by RNA interference. Target regions of the transcript are identified on the basis of hybridisation to scanning arrays of antisense oligonucleotides and siRNA reagents comprising double-stranded RNAs corresponding to the target regions... Agent: Foley & Lardner LLP

20070213285 - Methods and compositions for cancer therapy: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.... Agent: Jonathan P. O'brien, Ph.d. Miller, Canfield, Paddock And Stone

20070213290 - Neurite regeneration: The present invention relates to the use of RARβ2 and/or an agonist thereof in the preparation of a medicament to cause neurite development, neurite growth and/or neurite regeneration.... Agent: Frommer Lawrence & Haug

20070213287 - Nucleic acid formulations for gene delivery and methods of use: A nucleic acid formulation for use in gene delivery comprising a nucleic acid and an anionic polymer is disclosed. Examples of the anionic polymer includes anionic amino acid polymer or poly-amino acid (such as poly-L-glutamic acid, poly-D-glutamic acid, poly-L-aspartic acid, poly-D-aspartic acid), poly-acrylic acid, polynucleotides, poly galacturonic acid, and poly... Agent: Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.L.P.

20070213291 - Therapeutically useful synthetic oligonucleotides: The present invention provides a composition and method comprising a 2-20 base 3′-OH, 5′-OH synthetic oligonucleotide (sequence) selected from the group consisting of (GxTy)n, (TyGx)n, a(GxTy)n, a(TyGx)n, (GxTy)nb, (TyGx)nb, a(GxTy)nb, a(TyGx)nb, wherein x and y is an integer between 1 and 7, n is an integer between 1 and 12,... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20070213294 - Methods for modulating the axonal growth of central nervous system neurons: Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injury and the like) and methods for inhibiting the axonal outgrowth of central nervous... Agent: David S. Resnick

20070213296 - Compositions and methods for the treatment of immunoinflammatory disorders: The invention features methods and kits for treating an immunoinflammatory disorder, by administering to a patient diagnosed with or at risk of developing such immunoinflammatory disorder an adenosine activity upregulator in combination with one or more additional agents.... Agent: Clark & Elbing LLP

20070213295 - Methods and compositions for inducing torpor in a subject: The present invention relates to the discovery the 5′-AMP and analogues thereof can be used to induce a state of torpor or suspended animation in subjects, as exemplified by studies carried out in laboratory mice. In these studies, mice were injected with high doses of 5′-AMP, which was found to... Agent: Fulbright & Jaworski L.L.P.

20070213297 - Arrays with cleavable linkers: The invention provides arrays of molecules where the molecules (e.g., glycans) are attached to the arrays by cleavable linkers. The invention also provides methods for using these arrays, methods for identifying the structural elements of molecules bound to these arrays by using the cleavable linkers, especially the structural elements that... Agent: Frommer Lawrence & Haug

20070213298 - Omega 3: A process for the preparation of a water soluble unsaturated fatty acid salt from a crude composition comprising at least one non-water soluble or sparingly water soluble unsaturated fatty acid or salt thereof, said process comprising: adding to said crude composition in the presence of water at least one amino... Agent: Sutherland Asbill & Brennan LLP

20070213299 - Compounds and methods for controlling fungi, bacteria and insects: The present invention includes compounds of pyridinium salts and methods of their use for industrial uses. The present invention also relates to methods of controlling fungi and/or bacteria. The present invention may also be used to control insects.... Agent: Myers Bigel Sibley & Sajovec

20070213301 - Substituted aminothiazole derivatives with anti-hcv activity: and the variables R and R1 to R7 are described herein. These compounds are useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the... Agent: Cantor Colburn, LLP

20070213303 - Methods for reducing platelet activation and for the treatment of thrombotic events: d

20070213304 - Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome: A method for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhoea-predominant irritable bowel syndrome or other non-specific bowel disorder is disclosed comprising administering to a patient in need of such treatment or prophylaxis an effective amount of balsalazide, or a 4-ASA or 5-ASA compound modified to include a 4-ABA... Agent: Mcandrews Held & Malloy, Ltd

20070213305 - N-alkyl-n-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof: wherein Ar, R1-R4 and R10 are defined herein. The present invention relates to the discovery that compounds having Formulae I-II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070213306 - Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders: The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective... Agent: Sheppard Mullin Richter & Hampton LLC 1300 I Street Nw

20070213307 - Methods to treat autoimmune and inflammatory conditions: This invention provides methods for treating inflammatory or autoimmune diseases by contacting the affected cell or tissue with a therapeutic compound as described herein. Such pathologies include, but are not limited to rheumatoid arthritis, systemic lupus erythmatosus, psoriatic arthritis, reactive arthritis, Crohn's disease, ulcerative colitis and scleroderma. Therapeutic compounds useful... Agent: Foley & Lardner LLP

20070213308 - Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith: The invention features methods, compositions, and kits for treating a musculoskeletal disorder, e.g., osteoarthritis, or pain, fatigue, tenderness, impairment in mobility, soft tissue swelling, or bony swelling associated therewith, by administering to a patient diagnosed with or at risk of developing such pain, fatigue, tenderness, impairment in mobility, soft tissue... Agent: Clark & Elbing LLP

20070213310 - Prodrugs for use as ophthalmic agents: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070213309 - Sepsis treatment methods: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3η-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070213311 - Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.... Agent: Fish & Richardson PC

20070213312 - Hif-1 inhibitors and methods of use thereof: Methods of treating a cancer or tumor, chemopreventative methods of prophylactically treating cancers or tumors, pharmaceutical compositions, methods for the treatment or prevention of a hypoxia-related pathology, methods of modulating HIF-1 activity in a cell, methods of downregulating HIF-1 activity in a cell, methods of treating or preventing cancer or... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070213313 - Direct process for the production of an amino acid dihydrochloride: An amino acid in solution is precipitated with concentrated hydrochloric acid and isolated as the dihydrochloride monohydrate. Said dihydrochloride is redissolved and reprecipitated by adding a solvent.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070213315 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20070213314 - Dibenzyl amine compounds and derivatives: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels... Agent: Pfizer Inc.

20070213316 - N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives: b

20070213317 - Inhibitors of the mutant form of kit: The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.... Agent: Novartis Corporate Intellectual Property

20070213318 - Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment: The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure... Agent: Knobbe Martens Olson & Bear LLP

20070213319 - Modulators of hepatocyte growth factor/c-met activity: This invention is directed to compounds and compositions that have biological properties useful for modulating HGF/SF activity. In certain embodiments, said compounds and compositions may be used in the treatment and prophylaxis of cancer or other dysproliferative diseases, as well as inflammatory diseases such as rheumatoid arthritis.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070213320 - 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones: i

20070213321 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070213322 - Use: R3 is hydrogen, CH3 or fluoro; as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070213323 - Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) X R1 N Y (I) R2 R3 wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for... Agent: Gardner Groff Greenwald & Villanueva. PC

20070213324 - Stable pharmaceutical composition of carisoprodol and meloxicam: The present invention provides a pharmaceutical composition or formulation in the form of tablets of proved stability and describes the obtainment process. This formulation combines the therapeutic action of meloxicam as an anti-inflammatory and carisoprodol as and analgesic and anti-inflammatory. Administering the two components jointly produces beneficial results which are... Agent: Reinhart Boerner Van Deuren P.C.

20070213325 - Multi-cyclic compound and method of use: wherein A, B, C1, C2, D, L1, L2 and R3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2... Agent: Amgen Inc.

20070213327 - Pyrrolo [3,2-c] pyridines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20070213326 - Substituted indole compounds and their use as 5-ht6 receptor modulators: The present invention relates to substituted indole compound of general formula I, a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation of medicaments, which are suitable e.g. for the prophylaxis and/or treatment of disorders or diseases that... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070213328 - Pyridothiophene compounds: The use of compounds of formula (I) in therapy, particularly for the treatment of a disorder mediated by excessive or inappropriate HSP90 activity formula (I), wherein R2 is a group of formula (IA): -(Ar1)m-(Alk1)p-(Z)r-(Alk2)s-Q (IA) Ar1, Alk1, Z, Alk2 and Q being as defined in the specification; m, p, r... Agent: Banner & Witcoff, Ltd.

20070213329 - Sulphones which modulate the action of gammasecretase: e

20070213330 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070213331 - Pyrrolidine derivatives useful as base inhibitors: e

20070213332 - Prodrugs of substituted amino heterobicycles which modulate the function of the vanilloid-1 receptor (vr1): Compounds of formula (I) which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).... Agent: Merck And Co., Inc

20070213334 - Cannabinoid receptor ligands and uses thereof: Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.... Agent: Pharmacia Corporation Global Patent Department

20070213333 - Substituted arylalkanoic acid derivatives and use thereof: [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom... Agent: Birch Stewart Kolasch & Birch

20070213335 - Prolyl hydroxylase inhibitors: n

20070213336 - Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof:

20070213337 - Modulators of serotonin receptors: The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and... Agent: Louis J. Wille Bristol-myers Squibb Company

20070213338 - Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain: The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic,... Agent: Merck And Co., Inc

20070213339 - Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions: e

20070213341 - Spiroindolinone derivatives:

20070213340 - Farnesyl protein transferase inhibitors:

20070213342 - Novel 2-(1-aza-bicyclo[2.2.2.]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor: This invention encompasses nicotinic acetylcholine receptor reactive compounds in accord with formula (I) Wherein: D represents O; E represents CH2, NH, O or S; n is 1 or 2 and stereoisomers, enantiomers, in vivo-hydrolysable precursors and pharmaceutically-acceptable salts of such compounds, pharmaceutical compositions and formulations containing them, methods of using... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070213343 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070213344 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070213345 - Immuno inhibitory pyrazolone compounds: Compounds of formula (IA) or (IB) are inhibitors of CD80 and useful in immunomodulation therapy: wherein Ar represents an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group having from 5 to 10 ring atoms; R1 and R2 independently represent H, or C1-C6 alkyl; R3 represents H; F; CI; Br,... Agent: Banner & Witcoff, Ltd.

20070213346 - Substituted 4-alkyl-and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists: m

20070213347 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070213348 - Chemical compounds: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070213349 - Glucokinase activators: e

20070213350 - Method of treating ileus by pharmacological activation of cholinergic receptors: A method of treating ileus in a subject by administering to the subject an effective amount of a pharmacological agent that increases the activity of cholinergic receptor in a subject. Examples of pharmacological agents are brain muscarinic agonist, cholinergic agonist or cholinesterase inhibitor. The methods of the present invention can... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070213351 - Spirocyclic cyclohexane compounds: Spirocyclic cyclohexane compounds, methods for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds to treat and/or inhibit specific undesirable conditions in a patient.... Agent: Crowell & Moring LLP Intellectual Property Group

20070213352 - Pyridine-containing macroheterococylic compounds as kinase inhibitors: This invention is directed to pyridine-containing macroheterocyclic compounds useful as kinase inhibitors, methods for producing such compounds and methods for treating or preventing a kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20070213353 - Esters in position 20 of camptothecins: Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors.... Agent: Nixon & Vanderhye, PC

20070213354 - Compositions and methods for the treatment of multiple sclerosis: r

20070213355 - 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases: The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases,... Agent: Novartis Corporate Intellectual Property

20070213356 - Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines: Imidazoquinoline and imidazonaphthyridine compounds having a nitrogen-containing heterocyclyl substituent at the 5-, 6-, 7-, or 8-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and... Agent: 3m Innovative Properties Company

20070213357 - Use of glucosidase inhibitors for therapy of mucovisidosis: The invention relates to the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R1 represents a CH3 group, or CH2OH, R2 represents H or an alkyl group having 1-5 carbon atoms, or R1 and R2 together form a group having formula (II), with carbon in position... Agent: Young & Thompson

20070213359 - Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof: as defined herein, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, that modulates the activity of a ghrelin receptor. Disclosed herein are also methods of treating diseases or conditions that comprise administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.... Agent: Knobbe Martens Olson & Bear LLP

20070213358 - Pyrrolo[3,2-b]pyridine derivatives and processes for the preparation thereof: The present invention provides novel pyrrolo[3,2-b]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[3,2-b]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Sughrue Mion, PLLC

20070213360 - Tetrahydropyridothiophenes for use in the treatment of cancer: e

20070213362 - 2-nh-heteroarylimidazoles with antibacterial activity: A method of inhibiting MetRS activity comprises administering to a patient in need thereof a MetRS inhibiting effective amount of a compound of the formula (I). A method of treating a resistant or multiply-resistant E. faecalis infection, a resistant or multiply-resistant S. aureus infection, and/or a resistant or multiply-resistant S.... Agent: Swanson & Bratschun, L.L.C.

20070213361 - Preventive and/or therapeutic agent for neutrophilic inflammatory diseases: [wherein R1 represents a hydrogen atom, substituted or unsubstituted alkyl, or the like, A1-A2-A3-A4 represents N═CR3—CR4═CR5 (wherein R3, R4, and R5 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like), Q represents substituted or unsubstituted phenylene, and the like, and... Agent: Antonelli, Terry, Stout & Kraus, LLP

20070213364 - Alkoxyphenylpropanoic acid derivatives: wherein each symbol is as defined in the description, a salt thereof, and a prodrug thereof of the present invention unexpectedly have a superior GPR40 receptor agonistic activity and superior properties as pharmaceutical products such as stability and the like, and can be safe and useful pharmaceutical agents as agents... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070213365 - Novel polymorphs of montelukast ammonium salts and processes for preparation therefor: Novel crystalline forms I, II, III, IV, V, VI, VII, VIII, IX, and X of montelukast ammonium salts are provided, and novel methods of making these forms are disclosed.... Agent: Martin D. Moynihan Prtsi, Inc.

20070213363 - Tetrahydro-quinolinylurea derivatives: This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredi- ents of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR I) C antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in... Agent: Jeffrey M. Greenman

20070213366 - Treatment of synucleinopathies: Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, and Multiple System Atrophy, or other neurodegenerative diseases are provided. The treatment including administering to a subject a farnesyl transferase inhibitor compound.... Agent: Choate, Hall & Stewart LLP

20070213367 - Substituted 3-cyanoquinolines as mek inhibitors: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an... Agent: Morgan Lewis & Bockius LLP

20070213368 - N-ethyl hydroxyethylamine useful in treating cns conditions: An N-ethyl hydroxyethyleneamine of formula (I) are disclosed which are useful in treating CNS conditions, including neurodegenerative diseases such as Alzheimer's Disease.... Agent: Knobbe Martens Olson & Bear LLP

20070213369 - Novel non-psychotropic cannabinoids: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of Δ6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due... Agent: Winston & Strawn LLP Patent Department

20070213370 - 5-htp combination therapy: The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20070213371 - Dibenzyl amine compounds and derivatives: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels... Agent: Pfizer Inc.

20070213372 - Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands: b

20070213373 - Indazole derivatives as crf antagonists: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070213374 - Malonamide derivatives: The present invention relates to malonamide derivatives of formula A-D-B-1, as inhibitors of raf-kinase and the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition.... Agent: Heller Ehrman LLP

20070213375 - Triazole derivatives useful as axl inhibitors: Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20070213376 - Halogenated sulfonamide derivatives: This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20070213377 - Novel hexafluoroisopropanol derivatives: i

20070213378 - Compounds for modulating cell proliferation, compositions and methods related thereto: Compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070213379 - Malonamides and malonamide derivatives as modulators of chemokine receptor activity: m

20070213380 - Thiadiazoline derivative:

20070213382 - 2-methylthiazolidine-2, 4-dicarboxylic acid-containing combination preparations: The invention relates to a combination preparation of 2-methylthiazolidine-2,4-dicarboxylic acid and/or physiologically acceptable salts thereof and at least one cytotoxic and/or cytostatic compound as well as the use of these combination preparations for the treatment of cancer.... Agent: J C Patents, Inc.

20070213381 - Topical compositions comprising telmesteine for treating dermatological disorders: This invention relates to topical compositions, such as creams and lotions, that comprise or consist essentially of Telmesteine, or a pharmaceutically acceptable salt thereof, as the active ingredient, and methods for their use in treating a variety of dermatological diseases and disorders, including atopic, dermatitis (eczema), allergic contact dermatitis, seborrheic... Agent: Marshall, Gerstein & Borun LLP

20070213383 - Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity: There is provided a compound of Formula III or Formula IV wherein A is selected from H, OH, halogen and hydrocarbyl D, E and F are each independently of each other an optional linker group; P, Q and R are independently of each other a ring system, wherein R4 and... Agent: Frommer Lawrence & Haug

20070213384 - 4-amino-1,5-substituted-1,5-dihydro-imidazol-2-ones: e

20070213385 - New derivatives of 4,5,6,7-tetrabromobenzimidazole and method of their preparation:

20070213386 - Substituted pyrrolines as kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20070213387 - Substituted pyrrolines as kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20070213388 - Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of of cognitive disorders: The present invention relates to compositions and methods of treating a cognitive disorder in a subject by administering an effective amount of phenserine or a pharmaceutically acceptable salt thereof and an effective amount of memantine or a pharmaceutically acceptable salt thereof to a subject, thereby treating a cognitive disorder in... Agent: Trask Britt

20070213389 - Process and substances for the release of a growth-regulating factor from endothelial cells: A method of stimulating endothelial cells cultivated in a nutrient medium to release a growth-factor into the nutrient medium by addition of at least one pentacyclic oxindole alkaloid into the nutrient medium.... Agent: Lerner Greenberg Stemer LLP

20070213390 - Hmgcoa reductase inhibitor-angiotensin converting enzyme inhibitor compounds: A compound that contains at least two independently active pharmacological moieties, either covalently conjoined through a physiologically labile linker or ionically associated. One pharmacological moiety is an HMGCoA reductase inhibitor (such as a statin). Another pharmacological moiety is an angiotensin converting enzyme inhibitor.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070213391 - Furosemide modulators of hm74: Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070213392 - Thiophene and benzothiophene hydroxamic acid derivatives: The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070213393 - Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents: Disclosed herein are compositions and methods for treating a variety of inflammatory conditions (e.g., inflammatory arthritis, adhesions, tumor excision sites, and fibroproliferative diseases of the eye). For example, there is provided a composition comprising a protein or polysaccharide containing dispersed (e.g., in micelle or liposome form) anti-microtubule agent, which may... Agent: Seed Intellectual Property Law Group PLLC

20070213394 - Salvinorin derivatives and uses thereof: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.... Agent: Clark & Elbing LLP

20070213395 - Dietary supplement composition for blood lipid health: A human or animal dietary supplement composition comprising one or more long chain (C24-C36) primary alcohols (policosanols) dispersed in food-grade oils or fats where the policosanol particle size is substantially less than ten (10) microns. The composition (Nanocosanol™) is effective and convenient for supporting blood lipid health.... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20070213396 - Active substance combinations having insecticidal properties: The novel active compound combinations of triflumuron and the active compounds (1) to (24) listed in the description have very good insecticidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070213397 - Motuporamine mimic agents: Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.... Agent: Beusse Wolter Sanks Mora & Maire

20070213398 - Inhibitors of phosphatidyl myo-inositol cycle: The present invention relates to the preparation and biological activity of 3-deoxy-Dmyo-inositol ether lipid analogs as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. The compounds of the present invention are useful as anti-tumor 5 agents which effectively inhibit the growth of mammalian cells.... Agent: Pepper Hamilton LLP

20070213399 - Modulation of nitric oxide synthases by betaines: The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both... Agent: Hovey Williams LLP

20070213400 - Alcohol-metabolism enhancing composition and ingesta containing the same: An alcohol-metabolism enhancing composition contains theanine. The composition may be contained in ingesta. Theanine has an effect of quickly reducing blood alcohol concentration, thereby easing or improving troubles due to alcoholic ingestion such as hangover or alcoholic hepatic insufficiency.... Agent: Burr & Brown

20070213402 - Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease:

20070213401 - Pharmaceutical uses for alpha2delta ligands:

20070213403 - Tamoxifen response in pre-and postmenopausal breast cancer patients: The present invention relates to the use of an inhibitor of the VEGFR2 receptor in the preparation of a pharmaceutical preparation for improving tamoxifen treatment response in pre- and postmenopausal breast cancer patients being estrogen receptor positive.... Agent: Gauthier & Connors, LLP

20070213404 - Processes for preparation of polymorphic form ii of sertraline hydrochloride: Provided are processes for preparation of crystalline sertraline hydrochloride Form II substantilly free of other polymorphic forms of sertraline hydrochloride, preferably on an industrial scale.... Agent: Kenyon & Kenyon LLP

20070213405 - Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride: A novel crystalline form of a (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride compound, methods of producing the compound, and related methods of use including treatment methods and pharmaceutical compositions containing the compound.... Agent: Crowell & Moring LLP Intellectual Property Group

20070213406 - Anti-inflammatory analgesic external aqueus liquid preparation: An anti-inflammatory analgesic external aqueous liquid preparation that excels in percutaneous absorbability and applicability, and being stable over time. There is provided an anti-inflammatory analgesic external aqueous liquid preparation comprising diclofenac or its salt, a dibasic acid ester, a lower alcohol, and 0.05 to 0.45 wt % of thickening agent.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070213407 - Compounds to treat alzheimer's disease:

20070213408 - Use of acetyl l-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients: The use of acetyl L-carnitine, or one of its pharmaceutically acceptable salts, is described for the treatment of neu-ropathic pain in patients with type 2 diabetes not treated with insulin.... Agent: Lucas & Mercanti, LLP

20070213409 - Use of preparations for skin enzyme protection: A cosmetic preparation which comprises an active complex of panthenol, glycerol and citrate. The mass ratio of panthenol to citrate anion is from 25:1 to 5:1 and the preparation has a pH value of from 4.6 to 5.4 and an SCTE (Stratum Corneum Tryptic Enzyme) value of from 120 to... Agent: Greenblum & Bernstein, P.L.C

20070207945 - Extended cycle multiphasic oral contraceptive method: A multiphasic method of contraception comprising the steps of sequentially administering to a female of child bearing age a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about... Agent: Fitzpatrick Cella Harper & Scinto

20070207965 - Method for the treatment of skin fibrosis and suitable compositions for such treatment: A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-β, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-β, for the treatment of skin fibrosis by topical application. The method... Agent: Ladas & Parry

20070207972 - Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative edp-182: The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine:... Agent: Elmore Patent Law Group, PC

20070207981 - Micro-encapsulation of volatile compounds into cyclodextrins: a new technology to reduce post harvest losses: Systems are provided for preventing post harvest fungal diseases of food systems, such as but not limited to fresh produce, such as but not limited to berries (e.g., blueberries). For example, various anti-fungal compounds can incorporated or encapsulated into cyclodextrins, such as but not limited to α, β and/or γ... Agent: Howard & Howard Attorneys, P.C.

20070207944 - Blood pressure lowering oligopeptides: The present invention describes a process to produce IPP from a protein source whereby the ratio of IPP and VPP produced from the protein is at least 5, preferably at least 10 and more preferably at least 20, which comprises the use of a proline specific endoprotease.... Agent: Nixon & Vanderhye, PC

20070207946 - Dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.... Agent: Osi Pharmaceuticals, Inc.

20070207943 - Interleukins-21 and 22: The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and Interleukin-22 (IL-22), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070207947 - Stabilized peptides: The present invention therefore presents modules from which helical constraints can be built by very flexible strategies. The peptide bonds involved partially compensate the hydrophobic nature of the disulfide bonds, which are also included into the constraint strategy. Thus, the invention presents solutions, by means of which peptide bonds or... Agent: Jacobson Holman PLLC

20070207948 - Convergent synthesis for kahalalide compounds: New synthetic routes to kahalalide compounds are provided. These are based on convergent approaches using orthogonal protecting schemes, where a better control of the intermediates is taken. Kahalalide F or a mimic of kahalalide F is synthesised by coupling a cyclic part with a side chain fragment, e.g. according to... Agent: King & Spalding

20070207949 - Medicaments and methods combining a hcv protease inhibitor and an akr competitor: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of a hepatitis C virus (HCV) protease inhibitor and an aldo-keto reductase (AKR) competitor, for concurrent or consecutive administration in treating, preventing, or ameliorating one or more symptoms of HCV, treating disorders associated with HCV, or inhibiting cathepsin... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070207950 - Methods and compositions for regulating hdac6 activity: The present invention provides methods and compositions for inhibiting Hsp90 activity in a cell, comprising contacting the cell with an inhibitor of histone deacetylase 6 (HDAC6)... Agent: Myers Bigel Sibley & Sajovec

20070207951 - Treatment with cyclosporin a: Disclosed herein is a method comprising administering cyclosporin A topically to an eye of a person for the purpose of treating or preventing loss of vision from keratoconus.... Agent: Allergan, Inc.

20070207964 - Combined use of a glp-1 compound and another drug for treating dyslipidemia: Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.... Agent: Novo Nordisk, Inc. Patent Department

20070207957 - Composition for accelerating alcohol metabolism or relieving fatigue by gluconeogenesis: There is provided a composition useful for mitigating a physical burden and recovering from fatigue at the time of alcohol intake, within a safety dose of active ingredients. The composition is for accelerating alcohol metabolism and for relieving fatigue by gluconeogenesis in vivo, and is characterized by comprising an effective... Agent: Foley And Lardner LLP Suite 500

20070207953 - Host defense factor x (hdfx): The present invention relates to compositions and methods useful in medical prophylaxis and treatment of a mammalian subject before and after exposure of the subject to potentially lethal pathogens and other insults. More specifically, the present invention provides an isolated a natural host defense factor, or “HDFX”, which enhances an... Agent: Scully, Scott, Murphy & Presser, P.C.

20070207954 - Immunomodulatory protein cloned from ganoderma microsporum: An immunomodulatory protein is cloned from Ganoderma microsporum. Its molecular weight is 15863.79 Da. Its genome sequence and translated protein sequence are different from those protected by the known patent of glycoprotein LZ-8, which is isolated from the mycelium of G. lucidum and has immunomodulator effect, and its immunomodulator efficiency... Agent: Birch Stewart Kolasch & Birch

20070207962 - Intravenous blood-replacement solutions: A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates continuously in the animal body to oppose the effects of stress. The theory endeavors to fit all known facts, and is based on the... Agent: Cislo & Thomas, LLP

20070207952 - Long acting biologically active conjugates: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and... Agent: Proskauer Rose LLP

20070207958 - Method of treatment of diabetes and/or obesity with reduced nausea side effect: The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for... Agent: Jones Day

20070207960 - Mutants of the factor vii epidermal growth factor domain: The application relates to modified blood coagulation factor, sequences encoding such modified factors, processes for their production, and related pharmaceutical compositions comprising such factors and their uses. More specifically, the application relates to mutations in the human FVII EGF-1 domain, wherein said mutations were analyzed for clotting activity, amidolytic activity... Agent: David S. Resnick

20070207955 - Novel polypeptide and process for producing the same, and collagenase inhibitor: e

20070207956 - Stabilised solid compositions of factor vii polypeptides: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.... Agent: Novo Nordisk, Inc. Patent Department

20070207961 - Tnf-alpha variants proteins for the treatment of tnf-alpha related disorders: The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.... Agent: Morgan, Lewis & Bockius, LLP

20070207963 - Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.... Agent: Knobbe Martens Olson & Bear LLP

20070207959 - Use of pentagastrin to inhibit gastric acid secretion or as a diuretic: This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.... Agent: Beyer Weaver LLP

20070207967 - Peptide inhibitors of matrix metalloproteinase activity: The present invention relates to novel matrix metalloproteinase (MMP) inhibitors and down-regulators, to pharmaceutical compositions comprising these inhibitors/down-regulators, to the improvement of liposome targeting to cancer cells, to the use of the novel MMP inhibitors for the manufacture of pharmaceutical and research preparations, to a method for inhibiting and down-regulating... Agent: Birch Stewart Kolasch & Birch

20070207966 - Polymeric carrier for delivery of small interfering rna: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to... Agent: Alan J. Howarth

20070207968 - Peptidomimetic inhibitors of retroviral proteases and their use as antivirals: The patent describes new peptidomimetic inhibitors of retroviral proteases, in particular of human immunodeficiency virus (HIV) protease. These inhibitors comprise as the core structure a new diaminodiol isostere of the dipeptide Phe-Pro having four stereogenic centres. The inhibitors of the invention have been shown to inhibit HIV protease and can... Agent: William Collard Collard & Roe, P.C.

20070207969 - Treatment of cancers of lymphocytic cells with product r: A method of treating a patient suffering from cancers of lymph cells such as acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma comprises parenterally administering to said patient an effective acute lymphocytic leukemia treatment amount of Product R in a pharmaceutically acceptable formulation.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070207970 - Use of l-carnitine for the treatment of cardiovascular diseases: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and... Agent: Nixon & Vanderhye, PC

20070207971 - Neuraminidase inhibitor: e

20070207973 - 1,3,5-triazines for treatment of viral diseases: The present invention provides compounds and methods for treatment of viral diseases and cancer.... Agent: Townsend And Townsend And Crew, LLP

20070207974 - Functional and hyperfunctional sirna: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.... Agent: Kalow & Springut LLP

20070207975 - Materials and methods for treating and preventing her-2/neu overexpressing, fas-elevated cancer cells: The invention provides methods for treating cancer cells overexpressing Her-2/neu, the product of the erbB-2 gene, comprising administering a therapeutically effective amount of an unsaturated fatty acid. The cancer cells amenable to treatment exhibit relatively elevated activity levels of fatty acid synthase. Exemplary fatty acids useful in the methods of... Agent: Marshall, Gerstein & Borun LLP

20070207976 - Nucleic acids and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070207977 - Naphthalimide compositions and uses thereof: A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a naphthalimide and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the naphthalimide comprises amonafide (5-amino-2-[2-(dimethylamine)ethyl]-1H-benz[de-]isoquinoline-1,3-(2H)-dione). Antiproliferative agents of the invention comprise... Agent: Morgan, Lewis & Bockius, LLP

20070207978 - C-pyrazole a2a receptor agonists: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070207979 - Method of using adenosine receptor blockers during tissue ablation: A mammal undergoing an ablation procedure is treated for symptoms associated with adenosine by administering one or more adenosine receptor antagonists to the mammal prior to or during the procedure.... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070207980 - Chp-gemcitabine combination agents and their use as anti-tumor agents: The invention relates to combined agents comprising cis-hydroxyproline (CHP) and gemcitabine and to the use of said agents in tumor prophylaxis and therapy.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20070207982 - 17-phosphorous steroid derivatives useful as progesterone receptor modulators: The present invention is directed to novel 17-phosphorous steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by a progesterone or glucocorticoid receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070207983 - Use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome: The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the treatment and/or prevention of insulin resistance, diabetes mellitus type 2 and/or Metabolic Syndrome. In particular, the invention relates to the use of a sphingolipid with the... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20070207984 - Cyclohexylamino benzene, pyridine, and pyridazine derivatives: wherein Q1, Q2, RN, R1, R2, R5, R6, R7, R8, X1, X2, X4, and Y are as defined herein. Compounds of Formula (I) are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070207985 - Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors: e

20070207986 - Inositol pyrophosphates, and methods of use thereof: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphosphate (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to... Agent: King & Spalding LLP

20070207987 - Androgen modulators: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Warner-lambert Company

20070207988 - Topical skin care composition: A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.... Agent: Darby & Darby P.C.

20070207989 - Diterpene derivatives for the treatment of cardiovascular, cancer and inflammatory diseases: c

20070207992 - Geldanamycin derivatives and method of use thereof: The present invention relates to novel geldanamycin derivatives which have antitumor and antiparasitic properties. The geldanamycin derivatives disclosed herein have antitumor properties in humans due to their interaction with human heat shock protein 90 (hsp90). The human parasites Plasmodium falciparum, Trypanosoma Cruzi, and Leishmania donovani are lethally susceptible to exposure... Agent: Ian C. Mcleod Ian C. Mcleod, P.C.

20070207990 - Process for the preparation of phenylcarbamates: wherein R1 and R2 independently are hydrogen or a C1-6 alkyl; R3 and R4 are the same or different and each is a C1-6 alkyl; or R3 and R4 together with the nitrogen to which they are attached form a cyclic three to eight membered ring, with or without a... Agent: Ivor M. Hughes, Barrister & Solicitor, Patent & Trademark Agents

20070207991 - Substituted n-aryl heterocycles, process for their preparation and their use as medicaments: e

20070207993 - Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases: The present invention relates to molybdenum carbonyl complexes useful for inhibiting tumor necrosis factor (TNF) production and for treating inflammatory diseases.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070207994 - 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: e

20070207997 - Alpha carbolines and uses thereof:

20070207995 - Deazapurines useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20070207996 - Novel compositions and methods of treatment: Disclosed inter alia is the use of quinazolinone derivatives, which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The quinazolinone derivatives are administered with another chemotherapeutic agent selected from alkylating agents, antimetabolites, platinating agents, topoisomerase inhibitors, tubulin agents and signalling inhibitors (e.g.,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070207998 - Muscarinic antagonists with parp and sir modulating activity as agents for inflammatory diseases: x The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070207999 - New compounds: T

20070208000 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070208001 - Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.... Agent: Fish & Richardson PC

20070208002 - Method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms: The invention provides a method to effectively wean a woman from hormonal therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for... Agent: Organon Usa, Inc. Patent Department

20070208003 - Compounds and methods for treating dyslipidemia: e

20070208004 - Indol-1-yl-acetic acid derivatives: The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said... Agent: Dickstein Shapiro LLP

20070208005 - Tetrahydrobenzazepines as antagonists and/or reverse agonists of the histamine h3 receptor: The present invention relates to novel benzazepine derivatives having pharmaceutical activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070208006 - Derivatives of n-[phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics: are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070208007 - Amine-based compound and use thereof: e

20070208008 - Substituted sulfonamides and ureas useful for inhibiting kinase activity: Sulfonamide and urea compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula II are disclosed and claimed:... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070208009 - Combination of anti-hiv reverse transcriptase and protease inhibitors: The invention relates to an anti-HIV combination comprising (i) tenofovir or its disoproxil fumarate derivative; (ii) ritonavir; and (iii) TMC 114, useful for the treatment or prevention of HIV infections. It further relates to pharmaceutical formulations containing such combinations.... Agent: Philip S. Johnson Johnson & Johnson

20070208010 - Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is... Agent: Merck And Co., Inc

20070208011 - Supersaturated benzodiazepine solutions and their delivery: The invention describes supersaturated solutions of benzodiazepines, such as diazepam, glycofurol and water and their use for intranasal (NS) administration to combat various disorders.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070208012 - Modulation of pathogenicity: In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070208013 - Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis: This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.... Agent: Jeffrey M. Greenman

20070208014 - Novel 2-substituted benzimidazoles as selective androgen receptor modulators (sarms): The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20070208015 - Novel 2-substituted benzimidazoles as selective androgen receptor modulators (sarms): The invention provides compounds of the formula (I) or a salt, solvate or N-oxide thereof, wherein: R1 and R2 are the same or different and each is selected from hydrogen, saturated C1-3 hydrocarbyl, halogen and cyano; X is selected from C═O, C═S, C(═O)NH, C(═S)NH, C(═O)O, C(═O)S, C(═S)O and C(═S)S; R3... Agent: Heslin Rothenberg Farley & Mesiti PC

20070208017 - 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors: or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated... Agent: Merck And Co., Inc

20070208016 - Composition containing benzamidine derivative and method for stabilizing benzamidine derivative: The present invention provides a composition containing a benzamidine derivative that does not decompose even when placed under humidification conditions and a method for stabilizing a benzamidine derivative. According to the present invention, decomposition reaction of a benzamidine derivative can be suppressed by adding to a benzamidine derivative represented by... Agent: Birch Stewart Kolasch & Birch

20070208018 - Quinazoline derivatives: e

20070208019 - Vasculostatic agents and methods of use thereof: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070208022 - Hiv inhibiting 5-carbo- or heterocyclyl substituted pyrimidines: HIV replication inhibitors of formula (I) N-oxides, a pharmaceutically acceptable addition salts, a quaternary amines or a stereoisomeric forms thereof, wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; R2 is OH; halo; optionally... Agent: Philip S. Johnson Johnson & Johnson

20070208020 - P70s6 kinase modulators and method of use: The invention provides compounds and methods for inhibition of kinases, more specifically p70S6 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070208021 - Phenoxyacetic acid derivatives and drug comprising the same: (wherein Q is an optionally-substituted benzene or pyridine ring; R1 and R2 each are an optionally-substituted phenyl group or 5- or 6-membered aromatic heterocyclic group; X Y, and Z are independently C, O, S or N; R3 to R9 each are a hydrogen atom, a lower alkyl group, etc.; n... Agent: Sughrue Mion, PLLC

20070208023 - Cancer treatment method: A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070208024 - Histamine h3 receptor agents, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using... Agent: Eli Lilly & Company

20070208025 - Novel pyridazine derivatives and medicines containing the same as effective ingredients: wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted)... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070208026 - N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: Global Patent Group Attn: Ms Lavern Hall

20070208027 - Intermediate compounds for the manufacture of fused piperazin-2-one derivatives: m

20070208028 - Partial mglur5 antagonists for treatment of anxiety and cns disorders:

20070208029 - Modulation of neurogenesis by pde inhibition: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the... Agent: Townsend And Townsend And Crew, LLP

20070208031 - Substituted diketopiperazines as oxytocin antagonists: e

20070208030 - Tetrahydroindolone derivatives for treament of neurological conditions: Compositions comprising tetrahydroindolone derivatives in which the tetrahydroindolone moiety is covalently linked to a substituted arylpiperazine moiety and methods for treating neurological and psychiatric conditions using such compositions are disclosed.... Agent: Morrison & Foerster LLP

20070208032 - Chemical compounds: Compounds of formula (I) wherein R is methyl or mesyl; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Also described are processes for their preparation, pharmaceutical compositions containing it and their use in producing an elevation of PDH activity in a warm-blooded animal.... Agent: Morgan Lewis & Bockius LLP

20070208033 - Amine compound and use thereof: m

20070208034 - 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors:

20070208036 - Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them: R, R1 and Z1 to Z3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070208035 - Heterocyclic compounds and their use as aldosterone synthase inhibitors: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, W, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070208037 - Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines: e

20070208038 - 6-(2-fluorophenyl)-triazolopyrimidines, method for producing them, their use for controlling parasitic fungi and agents containing the same:

20070208039 - Fungicidal mixtures for controlling rice pathogens:

20070208040 - A2a adenosine receptor antagonists: The present invention relates to novel compounds that are A2A adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as obesity, CNS disorders, including the “movement disorders” (Parkinson's disease, Huntington's Chorea, and catelepsy), and cerebral ischemia, excitotoxicity, cognitive and physiological disorders, depression, ADHD, and... Agent: Cv Therapeutics, Inc.

20070208041 - Compositions for the treatment and prevention of heart disease and methods of using same: The combination of nitric oxide generating compounds which are not dependent upon aldehyde dehydrogenase for bioactivation, or are specifically targeted to nNOS or the sarcoplasmic reticulum of cardiac muscle cells, and xanthine oxidase inhibitors are effective in the treatment of heart disease, specifically congestive heart failure and ischemic coronary disease.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070208042 - Method of using vasoconstrictive agents during energy-based tissue therapy: A mammal undergoing an energy-based therapy is treated by administering at least one vasoconstrictive agent to the mammal prior to or during the procedure. The at least one vasoconstrictive agent is added in amounts sufficient to reduce or prevent vasodilation. This treatment method increases or promotes the size of the... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070208043 - Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.... Agent: Alcon

20070208044 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070208045 - Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof: The present invention provides sulfonylurea compounds of formula (VIII) and pharmaceutically acceptable derivatives thereof and a process for making thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Townsend And Townsend And Crew, LLP

20070208047 - Low dose therapy for treating viral infections: A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV), by administering a low dose of Elvucitabine to a patient suffering viral infection is provided herein. The Elvucitabine dosages provided herein for effective anti-viral therapy are approximately 10-fold less than the effective dosages of currently... Agent: Cantor Colburn, LLP

20070208048 - New aryl imidazoles and related compounds as c5a receptor modulators: Such compounds are ligands of C5a receptors. Preferred compounds of the invention act bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds... Agent: Neurogen Corporation

20070208046 - Pyridone derivative: [in the formula, R1 and R2 may be same or different and stands for H, etc., or R1 and R2 may form an aliphatic nitrogen-containing heterocyclic group together with the N to which they bind; X1-X3 may be same or different and stand for methine or N, provided not all... Agent: Merck And Co., Inc

20070208049 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof... Agent: Seed Intellectual Property Law Group PLLC

20070208050 - Process for preparing irinotecan: The present invention relates to a process for the preparation of pure irinotecan or salts thereof, and a process for the preparation of intermediate compound 7-ethyl-10-hydroxycamptothecin.... Agent: Dr. Reddy's Laboratories, Inc.

20070208051 - Novel n-(alkoxyalkyl) carbamoyl-substituted 6-phenyl-benzonaphthyridine derivatives and their use as pde 3/4 inhibitors: e

20070208052 - Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines: Thiazoloquinoline and thiazolonaphthyridine compounds having an aryloxy or arylalkyleneoxy substituent at the 6-, 7-, 8-, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral... Agent: 3m Innovative Properties Company

20070208053 - Fused heterobicyclic kinase inhibitors: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X5, X7, R1, and Q1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and... Agent: Osi Pharmaceuticals, Inc.

20070208054 - Macrocyclic factor viia inhibitors useful as anticoagulants: or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used... Agent: Louis J. Wille Bristol-myers Squibb Company

20070208056 - Piperidinyl derivatives as modulators of chemokine receptor activity: The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070208055 - Alternative synthesis of renin inhibitors and intermediates thereof: wherein R1 is halogen, C1-6halogenalkyl, C1-6alkoxy-C1-6alkyloxy or C1-6alkoxy-C1-6alkyl; R2 is halogen, C1-4alkyl or C1-4alkoxy; R3 and R4 are independently branched C3-6alkyl; and R5 is cycloalkyl, C1-6alkyl, C1-6hydroxyalkyl, C1-6alkoxy-C1-6alkyl, C1-4alkanoyloxy-C1-6alkyl, C1-6aminoalkyl, C1-6alkylamino-C1-6alkyl, C1-6dialkylamino-C1-6alkyl, C1-6alkanoylamino-C1-6alkyl, HO(O)C—C1-6alkyl, C1-6alkyl-O—(O)C—C1-6alkyl, H2N—C(O)—C1-6alkyl, C1-6alkyl-HN—C(O)—C1-6alkyl or (C1-6alkyl)2N—C(O)—C1-6alkyl; or a pharmaceutically acceptable salt thereof as well as key intermediates... Agent: Novartis Corporate Intellectual Property

20070208057 - Methods and compositions using thalidomide for the treatment and management of cancers and other diseases: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse... Agent: Jones Day

20070208058 - Stable pharmaceutical compositions and methods of making and using same: Stable compositions comprising ketotifen or a ketotifen salt and methods of preparing such compositions are provided. The pH of the compositions remains at less than about 5 during storage. The methods comprise preparing pharmaceutical compositions comprising ketotifen or a ketotifen salt, and adjusting their pH to less than 5, thus... Agent: Bausch & Lomb Incorporated

20070208059 - Therapeutic agents: The present invention relates to compounds of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20070208060 - Compounds for treating inflammatory diseases: The invention relates to the use of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070208062 - 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections: Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.... Agent: Morgan Lewis & Bockius LLP

20070208063 - Imidazole-based compounds, compositions comprising them and methods of their use: Imidazole-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20070208061 - Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors: The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070208065 - Hydroxamic acid derivative and medicine containing the same as active ingredient: A compound which inhibits the production of IL-6 and/or TNFα by inflammatory cytokines and is useful in the prevention of or treatments for diseases such as various inflammatory diseases in which these cytokines participate and autoimmune diseases. It is a hydroxamic acid derivative represented by the following formula (1): (1)... Agent: Sughrue Mion, PLLC

20070208064 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070208067 - Tablet formulations and processes: The present invention is directed to pharmaceutical formulations and tablet compositions of pharmacological active agents of Formula I that are estrogen receptor modulators, and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20070208066 - Er-beta-selective ligands: X is O or S; and R1, R3-R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.... Agent: White & Case LLP Patent Department

20070208068 - Aqueous composition comprising thiazole derivative: The present invention provides an aqueous composition comprising a thiazole derivative of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined above, or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alcohol, boric acid or its salt, and water.... Agent: Sughrue Mion, PLLC

20070208069 - Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to pharmaceutical formulations of an anhydrous crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20070208070 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070208071 - Oxidative degradation products of atorvastatin calcium: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.... Agent: Novartis Corporate Intellectual Property

20070208072 - Maleate salt of tegaserod and crystalline forms thereof: Provided is sesqui-tegaserod maleate and processes for preparation thereof.... Agent: Kenyon & Kenyon LLP

20070208073 - Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients: Disclosed are compositions having one or more statins from two different groups, 1) one or more lipophilic statins and 2) one or more hydrophilic statins. The present invention is also directed towards methods of treating patients with cardiovascular diseases and other vascular diseases, including but not limited to Diabetes Mellitus... Agent: Kilpatrick Stockton LLP

20070208074 - Methods and compositions for treating and preventing tumors: The present invention provides methods for reducing the growth or invasiveness of tumors.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070208075 - Pharmaceutical compositions: This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another... Agent: Novartis Corporate Intellectual Property

20070208076 - Intracorporeal medicaments for high energy phototherapeutic treatment of disease: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler, Ltd.

20070208077 - Adiponectin enhancer: An adiponectin enhancer comprising as an active ingredient sesamin and/or episesamin, or an analogue thereof.... Agent: Drinker Biddle & Reath (dc)

20070208078 - Novel phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient: R4 is —CH═CH—(CH2)p—CH3 (wherein p is an integer of 1 to 12), —CH(OH)—(CH2)q—CH3 (wherein q is an integer of 1 to 13), —CH(OH)—CH2—CH(CH3)—(CH2)2—CH═C(CH3)2, —CH═CH—CH(CH3)—(CH2)3—CH(CH3)2, —(CH2)2—CH(CH3)—(CH2)3—CH(CH3)2 or —(CH2)8—CH3], an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have antitrypanosoma activity, and accordingly are useful as drugs for preventing... Agent: Harness, Dickey & Pierce, P.L.C

20070208079 - Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases: which are inhibitors of nuclear factor kappa B (NF-κB) and inhibit the activity of the endothelin receptor for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-κB inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful... Agent: Passe' Intellectual Property, LLC

20070208080 - A composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases: Disclosed herein is a composition for preventing or treating pruritic or irritant skin diseases which comprises, as a vanilloid receptor antagonist, a thiourea derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, together with a pharmaceutically acceptable carrier.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070208081 - Oligomeric compounds: A method is provided for the synthesis of a compound of general formula H(OCH[CH3]CH2C[O])n—O-A-O—R wherein n is an integer of 3 to 10, A is the residue of a dihydsic alcohol and R is H, C1-4 alkyl or H(OCH[CH3]CH2C[O])n— comprising reacting a cyclic oligomer of (R)-3-hydroxybutyrate containing between 3 and... Agent: Nixon & Vanderhye, PC

20070208083 - Alkyl-substituted n-(4-hydroxy-3-methoxy-benzyl)-cinnamamides, pharmaceutical compositions and uses thereof: para-Alkyl-substituted N-(4-hydroxy-3-methoxybenzyl)-cinnamic acid amide compounds, processes for the preparation thereof, pharmaceutical compositions containing these compounds, and the use of these compounds for treating or inhibiting specific diseases or disorders.... Agent: Crowell & Moring LLP Intellectual Property Group

20070208082 - Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors: Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1.... Agent: Townsend And Townsend And Crew, LLP

20070208084 - Enantiomers of o-desmethyl venlafaxine: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central... Agent: Wyeth Patent Law Group

20070208085 - Potent cytotoxicity and inhibition of pan-cell cycle progression by an alkylating anthraquinone: The present invention generally relates to chemotherapeutic treatment of proliferative disorders, such as cancer. The invention more specifically relates to inhibition of pan-cell cycle progression with alkylating anthraquinones, which may inhibit mitotic commitment, lead to limited expression of G2 arrest and force cells to enter polyploidy via an aberrant mitosis.... Agent: Dla Piper US LLP

20070208086 - Ubiquinone analogs and methods of use: New ubiquinone and ubiquinol analogs are disclosed, as well as methods of making and using these compounds.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070208087 - Compounds, compositions and methods for the treatment of inflammatory diseases: where R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and... Agent: Proteotech, Inc.

20070208088 - Pqs: a new hydrotrope for solubilizing lipophilic compounds in water: wherein R11, R12 and R13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. L1 and L2 are linker moieties, which are members independently selected from substituted or... Agent: Morgan, Lewis & Bockius LLP (sf)